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The investigation of biological molecules through electrospray ionization mass spectrometry has 
expanded over the past 20 years.  With a nanospray source allowing small volumes to be 
analyzed, perturbation of the sampled system is kept to a minimum.  Two studies take advantage 
of the lack of perturbation to quantitate molecules within biological fluids.  The first focuses on 
the concentration of glucose in tears.   
A quantitative method is developed to determine the concentration of glucose in human 
tears.  Aqueous solutions of known glucose concentrations and induced tears are used to validate 
the method.  Non-diabetic and diabetic subjects’ tears are sampled.  After overnight fasting, non-
diabetic tear glucose concentration is shown to be 28 ± 14 µM.  Tear glucose concentrations 
from samples taken before and after a meal are compared to the subjects’ blood glucose 
concentrations.  
The second study that dealt with small biological fluid volumes sought to quantitate 
neuropeptides within a rat’s cerebrospinal fluid.  A tapered fused silica capillary is used to obtain 
cerebrospinal fluid in order to minimize damage to the brain.  It was demonstrated that the 
matrix in the collected biological fluid caused the limit-of-quantitation of the method to be above 
the neuropeptide concentration within the sample. 
 iv 
Protein-RNA complexes are also explored through ESI-MS.  The observation of proteins 
and RNA is demonstrated.  Further experiments are performed to determine how many 
monomers of neuroblastoma apoptosis-related protein bind to RNA during replication.   
In addition to these biological inquiries, a few silyl containing compounds are examined.  
Different ionization techniques and collision-induced-dissociation are used to characterize 
hexamethyldisiloxane, tert-butoxy trimethylsilane, and 2-trimethylsiloxy-propene to determine if 
they can differentiate volatile organic compounds.  Collision-induced-dissocitaion of the silyl 
ions with argon, acetone-d6, and propanal as the collision gas provided structural identification 
and possible isomer discrimination.  Results show that the ion originating from the loss of a 
methyl group from hexamethyldisiloxane can provide an avenue to distinguish between acetone 
and propanal. 
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1.0  INTRODUCTION 
The quadrupole-octopole-quadrupole (triple multipole) mass spectrometer with a custom-built 
electrospray ionization (ESI) source in the Grabowski group allows specific problems related to 
the quantification and characterization of biological molecules to be solved.  The mass 
spectrometer, known as the SWISS-484, consists of, in succession, an ionization source, a 
quadrupole (Q1) used as a mass analyzer, an octopole (O) used for collision-induced-dissociation 
reactions, a second quadrupole (Q3) used as a mass analyzer, a conversion dynode, and an 
electron multiplier as the detector.  The triple multipole has unique capabilities for the 
verification of structure, especially in mixtures, and for quantification at lower detection limits.1,2  
The ionization source consists of a nanospray emitter, based on Wilm and Mann’s design,3 and 
atmosphere-to-vacuum ion transfer optics.  The implementation of the nanospray source is a 
crucial aspect to the SWISS-484 for efficient quantification of biological molecules.   
The nanospray source uses a lower flow rate of the sample than traditional electrospray, 
to both decrease the volume of sample needed and increase the sensitivity of the method.4  Data 
in the literature suggests that nanospray sources are compatible with low nanomolar 
concentrations of biological samples (ex., 2 pM leucine-enkephalin5 and 130 nM carbonic 
anhydrase6).  If these advantages are general, they will allow biological specimens to be 
examined without the need for unrealistic collection volumes.   
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Analysis of small volumes initiated the discussion with the Asher group about glucose 
monitoring for Diabetes Mellitus.  Close monitoring of blood glucose is important in order to 
prevent complications from Diabetes.7  There has been significant research to produce a non-
invasive method to monitor blood glucose.8-11  One of the methods has examined tear fluid 
glucose as a surrogate for blood glucose.  Over the past 70 years there has been significant 
disagreement in the glucose concentration in tear fluid.  It has been stated that the discrepancy in 
reported glucose concentrations is due to the differing degree of irritation of the eye when 
sampling.12-14  To obtain reliable tear fluid data, irritation of the eye must be kept to a minimum; 
hence only one or two microliters of fluid can be sampled.  In collaboration with the Asher 
group, the determination of tear glucose concentration commenced with the use of isotopic 
dilution mass spectrometry.  Tear fluid of non-diabetic and diabetic subjects was analyzed to 
establish a population trend of tear glucose concentration.  Also, associated blood glucose and 
tear glucose concentrations were obtained to determine a blood-tear glucose relationship. 
Another project dealt with the detection of peptides in the interstitial fluid of the brain.  
Neuropeptides have been associated with many neurological disorders such as schizophrenia, 
depression, and chronic pain.15-17  The concentrations of the peptides within the interstitial fluid 
of the brain are needed to understand the relationship that the peptides have in signal 
transmission in regards to psychological functions and disorders.  Opioid peptides are a subset of 
neuropeptides which are known to modulate the pain response in the nervous system.16,17  The 
understanding of the quantitative release of these peptides into the interstitial fluid will be 
valuable in on-going research to improve the treatment of pain.  Previous research has been 
performed on these peptides with the use of dialysis probes.5,18  However, the insertion of 
dialysis probes has been shown to damage cells that end up surrounding the probe.19  The 
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damaged cells have the potential to change the composition of the adjacent interstitial fluid 
through the exposure of the cell’s interior.  The use of tapered fused-silica capillaries, which are 
less disruptive than dialysis probes, obtains interstitial fluid surrounding undamaged tissue.  With 
this unique collection technique (in collaboration with Professor Michael’s group) and 
subsequent tandem mass spectrometry (MS/MS) experiments, the identification and 
quantification of selected peptides in the fluid was attempted.       
The last project dealing with biology is to characterize proteins that regulate RNA 
splicing.  Gene expression which regulates cell development and function is dependent on the 
splicing event; however, the splicing mechanisms are not fully understood.20  Proteins which 
have been identified to have a role in the splicing mechanisms are the polypyrimidine-tract-
binding proteins (PTB) and neuroblastoma apoptosis-related protein (NAPOR).20,21  With the use 
of ESI-MS, the proteins’ amino acid sequence can be identified through a combination of 
digestion and collision-induced-dissociation (CID).  Also, the protein-RNA complex can be 
explored with the “soft ionizaton” of electrospray ionization which allows non-covalent binding 
to be transferred to the gas phase.   
The one project that does not partake specifically in biological fluids deals with the 
characterization of silicon containing compounds.  A method is sought to identify and quantify in 
real-time volatile organic compounds in a complex mixture.  The use of hydronium ion in 
chemical reaction mass spectrometry has been demonstrated to this end.22  One limitation to the 
hydronium ion is that it clusters with water which greatly complicates analysis.  The replacement 
of the hydrogen atoms with trimethylsilyl groups on the hydronium ion is one way to eliminate 
the clustering reactions since the trimethylsilyl cation has similar reactivity as a proton23 but does 
not cluster.  In this study three molecules (hexamethyldisiloxane, tert-butoxy trimethylsilane, and 
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2-trimethylsiloxy-propene) are ionized by way of electron ionization (EI), ESI, and atmospheric-
pressure chemical ionization (APCI).  The resulting ions are subjected to CID with argon, 
acetone-d6, or propanal as the collision gas to identify structure and to determine if any can 
differentiate isomeric volatile organic compounds. 
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2.0  THEORY AND INSTRUMENTATION 
Improvement of instrumentation, specifically the SWISS-484, can not be successful without 
fundamental information concerning electrospray ionization, quadrupoles, and collision-iduced-
dissociation.  For the SWISS-484 to be applicable in biological fluid quantitation the 
electrospray ionization source needed to be able to perform in the nanospray regime.  A 
nanospray source can increase the signal-to-noise ratio and provide longer analysis times on 
small volumes.  Additional knowledge about quadrupoles and collision-induced-dissociation 
allows the combination of source design, multipole analyzers, and fragmentation experiments to 
form a triple-multipole mass spectrometer.   
2.1 ELECTROSPRAY IONIZATION 
Electrospray ionization (ESI) is a widely used but not completely understood technique.  The 
ions detected are indisputably ions sprayed from the solution, however the mechanics of ion 
transfer to the gas phase from solution has not been unequivocally established.24  Theories have 
been published about the ion transfer method, but none have been demonstrated to be flawless.  
The spray process begins with an electrophoretic mechanism to form droplets from a solution 
contained within a capillary biased to several thousand volts.24  These droplets are charged due to 
the electrophoretic spray process and are thus attracted to the counter electrode.  The steps by 
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which charged, single molecules are formed from these droplets are where questions remain.  
Solvent evaporation, ion emission, and coulombic fission, seem to be the factors, weighted in an 
unknown way, that are necessary to describe the process.  Of particular note, the molecules can 
retain the multiple charges they possessed in solution leading to m/z values that other ionization 
methods can not produce.25  The charges can be from the addition of a proton or sodium (or other 
metal) ion or the removal of a proton, to produce positive or negative ions respectively. 
2.1.1 Spray Process 
The most simplistic view of an electrospray source contains a capillary with a few kilovolts 
applied to it and a counter electrode.  The solution that is within the capillary will experience the 
applied field to the capillary, causing the ions to propagate in accordance to the field lines 
established between the capillary and the counter electrode.  In the case of positive ion ESI, a 
positive voltage is applied to the capillary.  The positive ions will gather at the tip of the 
capillary, the farthest point from the applied voltage, forming a Taylor cone extending out of the 
capillary.26  Once the combined charges of the positive ions can no longer be held together by 
surface tension, droplets are emitted from the cone.  The droplets, with their abundance of 
positive charge, will be attracted by the counter electrode (Figure 2.1).  This flow of charge 
produces a current from the capillary to the counter electrode which is proportional to the 
solution flow rate (Vf) and the conductivity of the solution (K), equation 1.24  To determine the
  n < 0.5      (1) nf KVI )*(∝
required voltage to begin spraying, the electric field around the tip, produced by the voltage on
  6
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Figure  2.1:  Simple electrospray ionization setup 
 
the capillary, needs to be known.24  In equation 2, Ec is the electric field in the air around the tip,
)/4ln(/2 cccc rdrVE =        (2) 
Vc is the applied voltage, rc is the capillary radius, and d is the distance from the tip to the 
counter electrode. Smith24 derived equation 3 which describes the electric field needed for the
coon rE εθγ /cos2≈        (3) 
onset of spraying, where γ is the surface tension, θ is the half angle of the Taylor cone, and εo is 
the permittivity of vacuum.  To determine the voltage to initiate spray, equation 4 is produced by 
occon rrdV εθγ 2/cos)/4ln(≈       (4)  
the substitution of Eon from equation 3 into equation 2 as Ec, wherein Von is the required voltage 
to initiate spray and the rest of the parameters are as described above for equations 2 and 3.  
  7
 Table  2.1:  Onset voltages for 100% water with different nebulizers 
d (cm) 0.3 0.5 0.5 1.0 1.0
r c (µm) 5.0 5.0 7.5 10.0 12.5
V on (kV) 0.9 0.96 1.12 1.36 1.48
γ = 0.073 N/m θ = 49.3
 
Once the droplets are formed, they rapidly break apart to form charged single molecules.  As 
long as the droplet has a radius greater than 10 nanometers coulombic fission dominates the 
decrease in droplet size.26  As the solvent in the droplet evaporates (i.e., the solvent density 
decreases) the electrostatic repulsion increases until the Rayleigh stability limit (equation 5) is 
38 Rq oRy γεπ=         (5) 
nearly reached.  In equation 5 R is the radius of the droplet and qRy is the charge at which point 
the radius of the droplet creates a repulsion force of the surface charges equal to the surface 
tension of the droplet.  The repulsion force or coulombic fission is reported to create a slightly 
smaller (but still large) droplet with “a cloud of small droplets”.24  Afterward, the large droplet 
again undergoes evaporation until the Rayleigh stability limit is reached and the process is 
repeated (Figure 2.2).  The ‘evaporation then coulombic fission’ cycle repeats until the droplets 
are less than 10 nm in radius.   
Two different hypotheses exist to describe the final step in ion formation (i.e. once the 10 
nm radius threshold is reached).  The first is the ‘charge residue method’ introduced by Dole and 
co-workers.27  The method mimics coulombic fission throughout the transition from the spray to 
a single molecule.  With further support from Schmelzeisen-Redeker et al.28 the method appears 
to be valid until the droplet reaches a radius of 1 nm.  In contrast, ‘ion evaporation theory’29,30 
introduced by Iribaine and Thomson states that once a small enough size of droplet is reached 
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Figure  2.2:  Rayleigh stability limit pathway where N is the number of elementary charges on the droplet and 
R is the radius of the droplet in micrometers.26 
 
(sub 10 nm radius) an ion can then be directly emitted with a solvation shell (Figure 2.3).31  This 
expulsion of a single ion with its solvent shell is called ion emission or ion evaporation.  The 
solvent shell then evaporates to leave the charged single molecule.  Unlike the charge residue 
method, ion evaporation appears to be valid from the 10 nm to molecular radius.24  However 
both methods have flaws in predictions based upon subtle aspects and both have been criticized 
for failing to take into consideration all of the factors in the case of a microscopic droplet.24  At 
the current level of ESI theory development, neither ion evaporation nor the charge residue 
method have been established as a better model for ion production. 
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Figure  2.3:  Ion evaporation pathway26 where d is the radius of an ion plus its solvent shell and xm is the 
distance the ion and solvent shell has moved outside the droplet. 
 
2.1.2 Nanospray Properties  
Upon consideration of the different techniques being used today for analytical mass 
spectrometry, nanospray is arguably the most convenient for biological research.32  The major 
difference involved in the change from macrospray to nanospray is the flow rate that is applied to 
the sample.  For traditional macrospray a sample flow rate above 1 µL/min is typical.6  
Nanospray is usually defined by a flow rate of 10-50 nL/min while microspray has a flow rate in-
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between macrospray and nanospray.  The two benefits of the low flow rate are the extended 
period of time that given volumes of material can be analyzed and the need for a drying gas is 
eliminated.33  The extended period of time for analysis allows for multiple experiments to be 
performed, which can be especially valuable in the case of a triple multipole instrument like the 
SWISS-484.  Also, more averaging is possible the longer the sample can be analyzed, resulting 
in a better signal-to-noise ratio.  Because of the small amount of fluid flowing through the 
capillary, the need for assisting the desolvation of the analyte is greatly decreased,33 this is 
because the less fluid being sprayed over a given time produces smaller radius droplets.24  These 
droplets take less time to transform to a single ion state and fewer analytes are lost to incomplete 
desolvation, as compared to the higher flow rate techniques, eliminating the need for nebullizing 
or drying gas.  These factors allow the capillary to be placed on a direct line and closer to the 
orifice to the mass spectrometer.  The one major drawback to the use of the nanospray is that 
smaller capillaries are required for the low flow rates.  With the capillary orifice, around 10 µm 
in diameter, clogging becomes a regular occurrence.  Even though the samples can be, in 
principle, sprayed for longer times, the ion current must be monitored for the onset of tip 
blockage.  At this occurrence, the tip either must be opened by increasing the voltage on the tip 
or breaking off the end for a clear path or the tip must be replaced. 
2.1.3 Ionization Output  
The ions produced by the sprays are often unique to the electrospray technique.6  Since the ions 
are formed by evaporation and emission from the solvent, the molecules are usually intact and 
rarely are fragmented prior to analysis.  Because of the general lack of fragmentation, 
electrospray ionization is considered to be a “soft ionization” method.34  Along with the lack of 
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fragmentation, non-covalent complexes can remain intact through the spray process.35  This 
provides the unique possibility of solution phase complexes being characterized as gas phase 
ions.   
Since the ions are produced from the substances in solution, the type and intensity of ions 
created will depend on the pH and salt content of the solution.  Large molecules, such as those 
greater than 2000 Daltons, are likely to be able to accommodate several-to-many charges, 
converting the high molecular weight molecule into an “envelope” of lower m/z values (where m 
is mass and z is charge).  A change in pH may result in an increase or decrease in the number of 
charges borne by the molecule.  With an increased concentration of salt, the likelihood of the 
corresponding cation addition instead of a proton is amplified (e.q., MNa+ vs MH+). 
2.2 QUADRUPOLES 
The experiments performed on the SWISS-484 utilize the capabilities of the three multipoles.  
Each could act as a mass analyzer on its own or be combined together to perform MS/MS 
experiments.  The first and third multipole (Q1 and Q3) are quadrupoles which act as mass 
analyzers.  These two independently can be set to pass all ions, to allow a window of m/z(s) to 
pass through, or to scan from one m/z to another.  The particular m/z passed is contingent on the 
rf and dc voltages that are applied to the quadrupoles.36  The middle multipole is an octopole and 
acts as an ion guide between the two mass analyzers.  Collision gas can be introduced into the 
octopole (which is shrouded) to induce dissociation of the ions.1  Since the octopole guides all 
ions through its region, any ion that is produced or left unchanged from the collisions will make 
it to the octopole exit which is also the entrance to Q3. 
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All three multipoles use the principles of electric fields to enable them to perform as mass 
analyzers.  The identical rods (four for a quadrupole and eight for an octopole) are all aligned at 
a set radius of 1.148ro centimeters, where ro is the radius of each rod.36  The electric connections 
in a quadrupole are arranged as shown in Figure 2.4.  The basis of the selection process of the 
quadrupoles hinges on the stability of the path of an ion of a particular m/z value.36  With both 
voltages causing the ion to deflect according to the fields produced, both voltage values 
combined will determine which ions will have a stable path and make it through the quadrupole.  
The starting point in understanding which ions will have the stable pathway begins with equation 
6, wherein F is the force on the ion, m is the mass of the ion, and a is the acceleration in the x 
2
2
dt
xdmmaF ==         (6)  
direction.  In dealing with electric fields or potentials equation 6 can be rewritten as equation 7 
wherein P is the potential.  In a three dimensional electric field the potential will follow equation 
8 wherein ro is the radius of the circle of poles, λ, σ, and γ are weighting parameters for the three
dx
dPe
dt
xdm −=2
2
        (7) 
)(2 zyxr
PP
o
o γσλ ++=        (8) 
dimensions, and Po is the applied electric potential as in equation 9 where U is the dc potential, V  
tVUPo Ω−= cos         (9) 
the rf potential, and Ω the angular frequency.37  Taking the derivative of equation 8 in respect to 
either the x or y axis and the substitution of equation 9 into equation 8 provides equation 10.  
)cos(2
2
tVU
r
x
dx
dP
o
Ω−= λ        (10) 
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Figure  2.4:  Quadrupole configuration 
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Furthermore, substituting equation 7 into 10 produces equation 11.  With the purpose of 
)cos(2 22
2
tVU
r
xe
dt
xdm
o
Ω−−= λ       (11)  
simplification one sets z  to equation 12.  Hence equation 13 is equation 11 rewritten with the 
2/tΩ=ζ          (12) 
)2cos(2
4 22
22
ζλζ VUr
xe
d
xdm
o
−−=Ω       (13) 
substitution of z .  So for each axis the ion would have this force upon it.  However in the case of 
a linear multipole the z direction is unfocused so its weighting parameter is zero.  Equation 8 will 
have one less variable as in equation 14.  Taking into effect the Laplace conservation law, which 
states equation 15, the weighting parameter must then add up to zero for a linear
)(2 yxr
PoP
o
σλ −=         (14) 
0=∇P          (15) 
multipole.38  With γ equaling zero for the z direction and (l  – s ) equaling zero, equation 16 is 
λσ −=          (16) 
produced.  First rearranging equation 13 to the differential of equation 17, it can be simplified 
with the use of the Mathieu parameters,36 equations 18 and 19, to provide equation 20 which 
22222
2 2cos88
Ω+Ω
−=
mr
xVe
mr
xUe
d
xd
oo
ζλλ
ζ       (17) 
22
8
Ω= mr
Uea
o
λ          (18) 
22
4
Ω= mr
Veq
o
λ          (19)  
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xqa
d
xd )2cos2(2
2
ζζ −−=        (20) 
takes into effect only the x direction. To obtain the y axis, the use of equation 16 provides the 
substitution of equations 21 and 22 as the Mathieu parameters.  Finally the ion motion is 
governed in the x axis as determined in equation 23.  Using the Mathieu parameters as axis,
ayax −=          (21) 
qyqx −=          (22) 
0)2cos2(2
2
=−+ xqa
d
xd ζζ        (23) 
stability diagrams can be produced as in Figure 2.5.  The shaded areas describe an ion with a 
stable pathway.  Taking into effect both axis will produce the stability diagram of Figure 2.6.36  
An ion will be allowed to pass through a multipole where the x and y stable pathways cross.  
There are three distinct regions of stability, however the region closest to the origin is the only 
one that has been extensively studied and used.37  When scanning a range of m/z, one can use a 
fixed ratio for a/q (Figure 2.7a).  This ratio can be rearranged to be 2U/V (equation 24). 
 
V
U
Ve
mr
mr
Ue
q
a o
o
2
4
*8
22
22 =
Ω
Ω= λ
λ
       (24) 
Manipulating the rf and dc voltages on the poles will guide the stability region to the desired ion. 
Another feature of multipoles that can be easily understood from Figure 2.7b is the 
resolution of the scan line.  Changing the value of a/q or the slope of the scan line will increase 
or decrease the resolution.  If the scan line is tangent to the top of the stability region then the 
resolution will be very high but the intensity will be low.  A smaller slope of the scan line will 
produce poorer resolution but higher intensity due to the wider range of ions in the stable region.  
Thus the resolution can be changed according to the type of spectrum that is desired. 
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Figure  2.5:  Quadrupole stability plot - 1 dimension32 
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Figure  2.6:  Quadrupole stability plot - 2 dimensions32 
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Figure  2.7:  Quadrupole (a) scan line and (b) resolution 
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2.3 COLLISION INDUCED DISSOCIATION 
The triple multipole configuration can perform CID experiments by having the first multipole set 
to pass selected m/z, the second multipole acting as a collision cell, and the third multipole 
scanning for the fragment ions.  In these experiments a dissociation reaction occurs in the 
octopole (also known as the collision cell).  In a typical CID experiment, Q1 selects a single ion, 
the precursor ion, to pass through to the octopole.  Collision gas (i.e., argon) is placed inside the 
octopole to obtain a higher pressure (~5x10-5 Torr) than within the quadrupoles.  The higher 
pressure in the collision cell provides the opportunity for the ions to collide with neutral species.  
At 5x10-5 Torr a pentapeptide would have a mean free path of about 21 cm.  The collision 
between an ion and the collision gas can provide enough energy for fragmentation of the ion to 
occur.1  Q3 can then either be configured to scan all of the product ions, or monitor a single 
known fragment ion from the precursor ion.  The former method can be used to identify the 
structural composition of the ion entering the collision cell.1  The latter method is known as 
selected reaction monitoring (SRM) and maximizes the identification of the selected ion 
presence in solution.  Whereas the scanning procedure provides qualitative information, SRM is 
typically used for increased sensitivity for quantitative experiments.39   
To clarify the function of each multipole in a given experiment, a set of three rectangles 
will be utilized.  Four different graphics within the rectangles will signify if the multipole is 
functioning as an ion guide, scanning a range of m/z, functioning as a collision cell, or 
monitoring a single ion (Figure 2.8).  With the use of the graphic for the octopole functioning as 
a collision cell, the type of collision gas will be stated on the spectrum.  The graphic of the 
quadrupole monitoring a single ion will contain the m/z selected and the window width being 
passed in atomic mass units (amu).  Figure 2.9 shows a typical CID experiment set of rectangles. 
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0.7 amu
147
Ion Guide
 
 
Figure  2.8:  The multipole function clarification graphics: (upper-left) ion guide, (upper-right) scanning, 
(lower-left) collision cell, and (lower-right) single ion monitoring. 
 
 
0.7 amu
147
Q QO
argon
 
Figure  2.9:  Typcial CID experiment graphic where the first quadrupole is monitoring a single ion (m/z 147) 
with a width of 0.7 amu, the octopole is functioning as a collision cell with argon as the collision gas, and the 
last quadrupole is scanning a range of m/z.  
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2.4 SWISS-484 
The SWISS-484 consists of three main sections, the ionization interface, the multipoles, and the 
detector.  The ionization interface encompasses the electrospray mechanism and the transfer 
optics from atmospheric pressures to the vacuum chambers containing the multipoles.  The 
electrospray apparatus, Figure 2.10, has a syringe pump to provide a constant flow of solution.  
A connecting capillary carries the flow from the pump to the nebullizing capillary from which 
the spray occurs.  The connecting capillary is connected to the nebullizer capillary by a PEEK 
connector.  The nebullizer capillary is a 5 cm long, 360 µm OD, 25 µm ID fused silica capillary 
that has a pulled tip providing a smaller orifice.  The capillary is normally gold coated to provide 
the electrical connection to the high voltage required for electrospray ionization.  The tips we 
have used most often were purchased from New Objective, Inc.  The setup is connected to a 
Plexiglas mount (for electrical isolation) via a stainless steel bulkhead. 
 
To Syringe 
Pump
To High 
Voltage
SS 1/16” Bulkhead
Capillary Inlet to SWISS 484 
1.5 mm I.D.
Gold-coated Fused Silica Nebalizing Capillary 
360 um O.D. 25 um I.D.  10 um orifice
Fused Silica 
Connecting 
Capillary
Microtight Sleeve
PEEK ZDV Union
Plexiglass Mount
 
Figure  2.10:  SWISS-484 electrspray setup 
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The capillary inlet to the SWISS-484 is a 12 cm long stainless steel capillary with a 1.5 
mm ID.  The capillary is thermally isolated for heating, typically to 200oC, and the temperature 
is monitored via a thermocouple.  This capillary inlet begins the transfer of ions to the first 
quadrupole as summarized in Figure 2.11.  The skimmer_1 chamber is located directly after the 
capillary inlet and is terminated by skimmer_1 which contains a 1.0 mm ID orifice.  Following 
skimmer_1 is the skimmer_2 chamber which is terminated by skimmer_2 which contains a 0.75 
mm ID orifice.  Each skimmer chamber is evacuated by its own dedicated Pfeifer Balzers BZ 43 
model mechanical pump with a pumping speed of 4.44 L/s. After skimmer_2 is the source 
chamber which is evacuated by an Edwards Diffstak Model 160 oil-diffusion pump (700 L/s) 
backed by an Edwards E2M-18 mechanical pump (6.94 L/s).  An einzel lens is placed between 
skimmer_2 and the entrance to Q1.  The einzel lens consists of three lenses each with a 1 cm ID, 
a 4.6 cm OD, a 1.6 mm thickness, and spaced 1.5 cm apart.   
The other two sections of the SWISS-484 are the multipole chamber and the detector.  
They are evacuated by a Leybold-Heraeus 360 CSV Turbo pump with a pumping speed of 360 
L/s, backed by a Pfeifer Balzers BZ 43 mechanical pump with a 4.44 L/s pumping speed.  The 
multipoles are arranged in the following order (Figure 2.12): entrance lens, Q1 quadrupole, lens 
1_2, collision cell octopole, lens 2_3, Q3 quadrupole, and exit lens.  The four lenses each have a 
1 cm ID orifice and the multipoles are positioned equidistant between the adjacent lenses.  
Following the exit lens is the conversion dynode which is biased ±5000 V depending on the ions 
to be detected (negative or positive).  The dynode is followed by the electron multiplier.  Normal 
settings for the multiplier are 1800 V with a preamp gain of 1x109. 
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Figure  2.11:  SWISS-484 electrospray source 
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Figure  2.12:  SWISS-484 Design 
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The instrument controller is a Merlin Automation system version 1.0.15 from Extrel 
CMS with a CPU containing a 2.60 GHz processor and 1.0 GB of RAM.  The system was 
calibrated with three different compounds (Me4N+Cl-, polyethylene glycol (PEG), and 
myoglobin).   
The program Magic Transformer (MagTran) was used to deconvolute multiply charged 
ESI spectra.  MagTran was obtained from Zhongqi Zhang and uses a algorithm designed by 
Zhang and Alan G. Marshall.40  Deconvolution is needed for the high number of peaks in the 
analyte’s charge “envelopes”.  Raw data files were transferred to a text file of two columns, m/z 
and abundance (mV) by the Merlin Automation Data System and imported into MagTran.  On 
occasion analytes which contain only a few peaks are assigned by hand, based on the known 
molecular weights of the compounds in the solution. 
Me4N+Cl- was used to calibrate sub 200 m/z values.  A 23 µM solution in 50% methanol, 
50% water was used with a flow rate of 50 nL/min.  The New Objective tip with a 10 µm orifice 
had 2.0 kV applied to it.  The single ion ((CH3)4N+, m/z 74) and the aggregate (((CH3)4N+)2Cl-, 
m/z 183) were observed (Figure 2.13).   
Polyethylene glycol (PEG) with an average weight of 400 was used as a reference for the 
peptides, m/z range of 200 to 1000.  A 10 µM solution in 50% methanol and 50% water was used 
with a flow rate of 100 nL/min and with 2.0 kV applied to a tip with a 10 µm orifice.  The 
sodiated polymers, HO(CH2CH2O)nH(Na+), with between 5 and 15 repeat units were observed 
(Figure 2.14).   
Horse heart myoglobin (molecular weight is 16951.4 amu) was used as a reference for 
the proteins; the majority of which contain signals above m/z 1000.  A 4.5 µM solution in 25% 
methanol and 75% water containing 1% acetic acid was used with a flow rate of 300 nL/min and 
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with 2.0 kV applied to a tip with a 15 µm orifice.  The “envelope” of the addition of 10 to 20 
protons to the molecule is observed (Figure 2.13).  MagTran provided a molecular weight of 
16973.3 amu which has a 0.13% difference compared to the known value of 16951.4 amu for 
horse heart myoglobin. 
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Figure  2.13:  Spectrum of tetramethylamine (23 µM in 50:50 methanol:water) 
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Figure  2.14:  Spectrum of polyethylene glycol 400 (10 µM in 50:50 methanol:water with addition of NaCl to 
promote sodiation) 
 
  28
MagTran: 16,973.3 amu
Known: 16,951.4 amu
% difference:  0.13%
 
 
Figure  2.15:  Spectrum of myoglobin shown in Magic Transformer (4.5 µM in 75:25 methanol:water with 1% 
acetic acid).  The lower spectrum is the raw data with letters (A, B, C, …) signifying an “envelope” and 
numbers (15, 16, 17, …) signifying the number of protons on the structure.  The upper spectrum is the 
deconvoluted output showing the molecular weight and abundance of each “envelope”.  
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3.0  GLUCOSE 
The elevation of blood glucose due to poor insulin production and/or poor insulin action defines 
Diabetes Mellitus.41  Glucose monitoring is important in order to prevent complications resulting 
from the high blood glucose concentrations.7  The prevalent method to monitor glucose relies on 
a finger stick and a glucose oxidase based meter.   To alleviate the pinprick there has been 
significant research to produce a non-invasive method to monitor blood glucose.8-11  Some of the 
research has examined tear fluid glucose as an indicator for blood glucose; however, there has 
not been a definitive answer to the concentration of glucose present in tears.42  Section 3.1 
provides details about the tear glucose discrepancy over the past 70 years and is taken from Baca 
et al. (Chapter 5)43.  A few studies make a significant observation that irritation of the eye causes 
higher glucose concentrations in tears.12-14  This observation makes the method of sampling tear 
fluid critical dependent on the type of tears desired.  To obtain tear glucose concentrations of 
common/non-stimulated tears, less than 2 µL of fluid can be sampled due to the low volume of 
tear fluid (~7 µL) on the eye.  Electrospray ionization mass spectrometry (ESI-MS) can easily 
analyze microliter sized samples.  A method is developed utilizing 1 µL capillaries and ESI-MS 
to determine tear glucose concentrations.  With this method a correlation then could be 
determined between blood and tear glucose. 
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3.1 LITERATURE REVIEW 
Daum and Hill 12 reviewed the experimental data available in 1982, and noted that reported 
values of tear glucose in normal individuals range between 0 and 3.6 mM (65 mg/dL), with the 
median values ranging between 110 and 280 µM (1.98 and 5.04 mg/dL).  More recently, 
capillary electrophoresis and laser-induced fluorescence measurements of tear glucose 
concentration in a single subject found a glucose concentration of 138 µM (2.49 mg/dL).44  A 
study by this group on six non-diabetic adults found glucose concentrations ranging between 128 
and 166 µM (2.31 and 2.99 mg/dL) with an average of 139 µM (2.50 mg/dL).45  
A recent study by Lane et al.46 compared tear glucose values in 48 diabetic and 73 non-
diabetic subjects.  They found average tear glucose concentrations of 160 µM (2.9 mg/dL) for 
non-diabetic subjects and 350 µM (6.3 mg/dL) for diabetic subjects.  These average 
concentrations include measurements of tear samples taken before and after a carbohydrate load.  
The reported range of tear glucose concentrations was exceptionally high, ranging from below 
the limit of detection to 5.7 mM (103 mg/dL) for non-diabetic subjects and from below the limit 
of detection to 9.1 mM (164 mg/dL) for diabetic subjects.   
Van Haeringen and Glasius specifically addressed the dependence of tear fluid glucose 
on the method of collection.13  They used a glucose dehydrogenase method to analyze 
chemically stimulated tears collected with a capillary and non-chemically stimulated tears 
collected by contact with filter paper.  They found higher glucose concentrations in the tears 
collected by filter paper.  Van Heringen and Glasius concluded that the increased tear glucose 
concentration found in tears collected by filter paper is due to the mechanical stimulation of the 
corneal and conjunctival epithelium, and noted similar findings in previous experiments on 
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rabbits.14  Daum and Hill found increased tear glucose concentrations in subjects immediately 
after swimming.12  This increase was ascribed to mechanical or osmotic stress.   
While previous studies generally report increased tear glucose concentrations with 
increased blood glucose concentrations, many used very irritating collection methods, and some 
required large (stimulated) tear volumes for glucose measurements.  These results are not clearly 
germane for understanding basal tear glucose concentrations.  Lane et al. see a clear increase in 
average tear glucose concentration with increased average blood glucose concentration for 
diabetic subjects undergoing a glucose tolerance test.46  Unfortunately, they do not present data 
from individual subjects, but only population averages at various time points. 
Recently, two groups studied contact lens-based glucose sensors using glucose-
dependent, boronic acid fluorophores.10,47  In a clinical trial including four subjects, these 
glucose sensing contact lenses showed clear correlations between the fluorescence intensity and 
blood glucose concentrations upon feeding.  However, these studies did not correlate 
fluorescence intensity with absolute glucose concentrations.11  Initial clinical testing of a 
holographic glucose sensor in a contact lens also indicated a correlation of tear and blood 
glucose by demonstrating that the diffracted wavelength of light tracked the blood glucose 
concentration.47  This study also measured only relative glucose concentrations and did not 
correlate peak wavelength shift with absolute tear glucose concentrations.  
A recent study of five critically ill patients found a mean tear fluid glucose concentration 
of 7.25 ± 5.47 µM (0.13 ± 0.10 mg/dL), and found no statistically significant correlation between 
tear and capillary blood glucose concentrations (R2=0.052, p=0.12).48  However, as these patients 
were critically ill, the relevance of the results to normal and healthy diabetic subjects is 
questionable (Luis A. Colon, Personal Communication, 8/7/06). 
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3.2 EXPERIMENTAL 
Two ESI-MS instruments were used for the experiments, the SWISS-484 (described in Chapter 2 
section 2.4) and the HP LCMS 1000.  Glucose, 13C6-glucose, acetonitrile, acetic acid, and salts 
(NaCl, KCl, and Pb(NO3)2) were purchased from Sigma Chemical Company (St. Louis, MO).  
They were dissolved in water, with acid or salts already added, and then acetonitrile.  For 
experiments on the SWISS-484, solutions were sprayed from a New Objective capillary tip with 
an orifice of 10 µm with 2.0 kV applied to the spray tip and with a flow rate of 100 nL/min set on 
the syringe pump.  Data were collected for five minutes and all scans were averaged to provide 
the spectra.  Experiments performed on the HP LCMS were conducted as described in Chapter 4 
section 4.3. 
3.3 INITIAL RESULTS 
To maximize the sensitivity, lower the detection limit, and have conclusive evidence of glucose, 
MS2 experiments were determined to be the best avenue to obtain quantitative data.  Experiments 
were initiated on the SWISS-484 due to its tandem mass spectrometry capabilities.  Known 
solutions of glucose were characterized on first the SWISS-484 and then later on the HP LCMS.     
3.3.1 SWISS-484  
Solutions ranging from 20 mM to 100 µM of glucose in 50% water and 50% acetonitrile were 
analyzed.  In each spectrum only the sodiated peaks were observed (Figure 3.1).  To determine if 
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different adducts of glucose could be observed, acetic acid or salts (KCl and Pb(NO3)2) were 
added to the solution.  The addition of acetic acid to the above described solutions, to promote 
protonation, did not provide protonated glucose and sodiated glucose was still abundant.  With 
potassium chloride (2 mM) in a solution of 50 µM glucose, potassium-glucose adduct ion along 
with sodiated glucose along with each cationized glucose dimer were observed.  The intensities 
of the potassium-glucose adduct peaks were 20% of the sodiated peaks in the corresponding 
solutions (2 mM NaCl and 50 µM glucose) spectrum.  With the addition of lead nitrate (9 µM) to 
a 40 µM glucose solution, (glucose-H+)Pb2+ was observed but half as intense as sodiated glucose. 
With the sodiated ion the most intense of all ions, m/z 203 was used for quantitative analysis.   
 
150 450m/z
(glucose)Na+
(glucose)2Na+
(glucose)H+ (glucose)2Na+
 
Figure  3.1:  Spectrum of glucose (20 mM) solution taken with the SWISS-484 
 
To make sure that glucose and not other hexoses were being measured MS2 data was 
found in the literature demonstrating hexose differentiation.  Most hexoses fragment into 
identical product ions not allowing the identification through unique fragment ions to be 
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possible.  Salpin et al.49 showed that CID of Pb2+ cationized hexoses produced signature 
abundance ratios that can be used to differentiate hexose isomers.  As described above, the 
SWISS-484’s sensitivity to lead cationized glucose is less than to that of sodiated glucose.  Add 
this reduced sensitivity to the fact that the SWISS-484 at present has a detection limit for glucose 
just below one micromolar, fragmentation studies would not be helpful. 
Without the ability at present to use the MS2 method, proof that glucose is the only 
hexose in tears and verification of glucose quantitation by single quadrupole MS was needed.  
Out of all of the hexoses, glucose is the only sugar typically found above the 1 millimolar in 
blood.  Any hexose transfer from the blood will reflect this concentration dominance.  To our 
knowledge, glucose is the only hexose found in tears above micromolar concentrations.50-52  To 
facilitate quantitation of glucose, an isotopic dilution method was utilized.  In the method a 
known amount of a glucose isotope is added to the sample.  In the spectra of the sample the 
intensity ratio of the natural glucose ion to the glucose isotope ion is representative to the 
corresponding concentration ratio.  The unknown concentration of the natural glucose can then 
be calculated from the known concentration of the isotope and the intensity ratio.  Using an 
isotope of glucose prevents the need to worry about ionization discrepancies that would occur if 
one used a different molecule.2,53  Since the isotope has an identical structure as natural glucose, 
any effect occurring in the method would influence glucose and the isotope in the same way.  For 
the initial part of this study 13C6-glucose was employed as the standard since the addition of 6 
daltons to the mass was away from any interference in the spectrum for the SWISS-484.     
  35
3.3.2 HP LCMS  
With the decision to not pursue the MS2 data, a triple multipole instrument was no longer a 
necessity.  Experiments were now performed on the HP LCMS which is a single quadrupole 
mass spectrometer.  The use of the HP LCMS instead of the SWISS-484 had a couple 
advantages.  The LCMS system has an autosampler and the ability to perform flow-injection 
analysis.  The autosampler provides high throughput of samples which was needed due to the 
many tear samples that would be collected.  The flow-injection analysis allows sample spectra to 
be compared to background spectra which are contained at different time points of a single 
experiment.  Also, multiple injections can be performed in a row in one continuous experiment.  
Any fluctuations occurring to the background over the course of the injections can be easily seen 
in the total ion chromatogram.  This advantage became apparent when the intensity of sodiated 
13C6-glucose was studied.  During multiple injections (typically 15) in a single run, which lasted 
over 30 minutes, the background at m/z 209 fluctuated greatly.  This could normally be cancelled 
out with flow-injection analysis but the change in slope of the fluctuations was too high to obtain 
an accurate glucose measurement.  Ideally the background would be stable and any increase in 
intensity would be a result from the analyte.  With fluctuations in the background signal, the 
subtracted background no longer is equal over time in the analyte peak.  One way to solve this is 
to extrapolate the background before the analyte peak to the background after the analyte peak.  
However, if the fluctuations are too great then one has to question the validity of the 
extrapolation.  To solve this problem, the signal of m/z 205 was monitored and found to have a 
stable background and the isotope used for quantitation was changed to glucose-d2.  Another 
advantage in using the HP LCMS was that the only observed ion for glucose was the sodiated 
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monomer unlike the SWISS-484 where the dimer also was observed.  Having the analyte at one 
m/z allows the possibility to increase the signal-to-noise. 
As the development of the method progressed, it came apparent that the detection limit 
needed to be lowered to determine tear glucose concentrations.  A C18 column was added online 
prior to the mass spectrometer to separate glucose from the other constituents within tears.  By 
using the C18 column, compared to no column, the signal-to-noise ratio for glucose was increased 
(Figure 3.2) and the limit-of-quantitation was lower by a factor of ten.  The analysis difference 
can also be seen in the meal studies described and shown in Appendix A.  The complete final 
method is described in Chapter 4. 
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Figure  3.2:  ESI-MS spectra (m/z 190 – 240) of glucose in different matrixes: a) 100 µM glucose in water, 
b) 100 µM glucose in artificial tear fluid, c) onion-induced tears (estimated to be ~200 µM glucose based on 
other experiments), and d) non-stimulated tears (estimated to be ~70 µM glucose based on other 
experiments).  All samples were injected directly to the mass spectrometer for panels a, b, c, and d; no 
separation column was used.  The same samples were analyzed with the addition of a C18 column (a’, b’, c’, 
and d’).  Insert in d’ is a close-up of m/z 200 – 209 of d’. 
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4.0  ANALYSIS OF TEAR GLUCOSE CONCENTRATION WITH ELECTROSPRAY 
IONIZATION MASS SPECTROMETRY 
This work was published as: 
Christopher R. Taormina, Justin T. Baca, David N. Finegold, Sandford A. Asher, and 
Joseph J. Grabowski.  Journal of the American Society for Mass Spectrometry.  2007, 18, 332.42 
4.1 ABSTRACT 
We have developed a mass spectrometry-based method which allows one to accurately 
determine the glucose concentration of tear fluid.  We used a 1 µL micro-capillary to collect tear 
fluid from the tear meniscus with minimal irritation of the eye.  We analyzed the 1 µL volume of 
collected tear fluid with liquid-chromatography electrospray ionization mass spectrometry with 
the use of D-glucose-6,6-d2 as an internal standard.  Repeated measurements and a recovery 
experiment on pooled, onion-induced tears showed that the analysis of the glucose in tears was 
precise (4% relative standard deviation) and provided 100% recovery.  We found the tear 
glucose concentration of one fasting non-diabetic subject to be 13 to 51 µM while the onion-
induced tear glucose concentration of a different non-diabetic subject to be 211 to 256 µM. 
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4.2 INTRODUCTION 
In the United States, 9.6% of the population over 20 years of age and 20.9% of the population 
over 60 years of age have Diabetes Mellitus41.  The Diabetes Control and Complications Trial 
has shown that close monitoring and tight control of blood glucose concentration is critical in 
preventing the complications of Diabetes7.  Current self-monitoring methods rely on invasive 
finger sticks to directly measure blood glucose levels to provide the critical information required 
to achieve glycemic control.  A number of non-invasive approaches to monitoring blood glucose 
concentrations are being pursued; however, none have been successfully developed to the point 
where they have gained widespread clinical acceptance54.  There has been significant recent 
activity in exploring non-invasive monitoring by using tear fluid glucose as an indicator for 
blood glucose9,11,55.  Such an approach will be effective only if the glucose concentrations in tear 
fluid are a reliable surrogate for blood glucose concentrations.   
A survey of the literature over the last 70 years on tear glucose determinations indicates 
significant disagreement in measured tear glucose concentrations and on the relationship of tear 
fluid glucose to blood glucose concentrations.  Daum and Hill12 noted in their 1982 review of the 
human tear glucose literature that reported values of tear glucose in normal individuals range 
between 0 and 3600 µM with the median values between 110 and 280 µM.  More recently, a 
study of six non-diabetic adults found glucose concentrations in tear fluid ranging between 128 
and 166 µM with an average of 139 µM45.   
The differences in tear glucose concentrations between these reports are likely due to the 
use of different tear fluid collection methods.  Van Haeringen and Glasius specifically addressed 
the dependence of tear fluid glucose on the method of collection13.  They used a glucose 
dehydrogenase method to analyze chemically stimulated tears collected with a capillary and 
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mechanically stimulated tear fluid collected by filter paper.  Van Haeringen and Glasius found 
higher glucose concentrations in the tear fluid collected by the filter paper and concluded that the 
increase is due to the mechanical stimulation of the corneal and conjunctival epithelium13.  Other 
studies reported similar findings in experiments on rabbits14 and in subjects that were tested 
immediately after swimming12.  Therefore, it is apparent that to determine a physiologically-
relevant, baseline tear glucose concentration, tear fluid must be acquired with minimal tear 
stimulation and eye irritation.     
Several previous studies used mass spectrometry to analyze tears for constituents other 
than glucose.  Fung et al.50 characterized the protein profile in the human tear fluid with MALDI-
ToF and electrospray ionization mass spectrometry.  Ham et al.51 identified the lipid profile in 
tear fluid and reported on their variations between normal and dry eyes.  There have been many 
reports of glucose measurement by mass spectrometry on bodily fluids other than tears.  The 
majority of these studies use gas chromatography and an electron ionization source56-59.  With 
gas chromatography, glucose typically needs to be derivatized to make it more volatile.  Other 
studies used liquid chromatography to bypass the volatility issue60,61.  Sodium62, lithium63,64, 
cesium60, and chloride65 ions have been used with electrospray ionization to form the cationic 
adduct of glucose from aqueous solutions.   
We discuss here a new, robust method of determining physiological tear glucose 
concentrations by using electrospray ionization mass spectrometry (ESI-MS). This method 
enables reliable studies of tear glucose concentrations in tear fluid. We use a tear fluid sampling 
method that is minimally irritating to the eye to collect 1 µL tear samples. We validate the ESI-
MS method by using glucose standard solutions, artificial tear fluid, and large volumes of 
stimulated tears. We determine tear glucose concentration in a non-diabetic, fasting adult. 
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4.3 EXPERIMENTAL 
All tear samples were collected and transferred with 1 µL “Microcaps” micro-capillaries 
(Drummond Scientific Company, Broomall, USA).  The tear film meniscus on the bottom eyelid 
was visualized using a slit lamp ophthalmic microscope (American Optics, Burlington, Canada).  
The micro capillary was gently touched to this tear fluid meniscus and the tear fluid was drawn 
in by capillary action.  During half the collections, there was inadequate tear fluid to immediately 
fill the capillary with one touch.  In these cases, the subject was asked to blink in order to 
redistribute the tear fluid and the capillary was again touched to the meniscus.  This process was 
repeated until the capillary was completely filled.  A few samples required as many as five 
repetitions of this process.  Care was taken throughout tear fluid collection to avoid stimulation 
of reflex tearing.  The aqueous glucose standards were collected and transferred with the same 
process as a tear sample; the capillary was touched to the solution surface and was filled by 
capillary action.  For studies involving larger volumes of stimulated tears, the subject chopped 
onions until tearing was induced.  These tears were collected by capillary action with glass 
Pasteur pipettes (2 mL) and pooled for each subject in order to analyze a homogeneous sample. 
Immediately after collection, the tear sample was transferred to a glass vial (Agilent, Palo 
Alto, USA) with a glass insert (Restek, Bellafonte, USA) containing 10 µL of acetonitrile 
(Mallinckrodt Baker, Inc., Phillipsburg, USA) and 10 µL of an aqueous stock solution of 
isotopically labeled glucose (D-glucose-6,6-d2, 99% labeled, Cambridge Isotope Laboratories, 
Andover, USA) used as an internal standard.  A typical value for the concentration of the D-
glucose-6,6-d2 stock solution was 27.5 µM, corrected for the 99% labeling (leading to a D-
glucose-6,6-d2 concentration of 13.1 µM in the sample injected into the mass spectrometer).  The 
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vials were then shaken and centrifuged for five minutes to ensure mixing and that the liquid was 
collected at the bottom of the vial.  The samples were refrigerated at 5oC until analyzed.   
Glucose concentrations were measured using ESI-MS.  Samples were analyzed by flow 
injection analysis on a HP 1000 LC-MS (Agilent, Palo Alto, USA).  Initial studies used an 
autosampler connected directly to the mass spectrometer.  However, our optimized method used 
a 2 µm filter and a Nova-Pak C18 3.9 x 150 mm column (Waters, Milford, USA) placed in-
between the autosampler and the mass spectrometer.  In both methods, the mobile phase 
consisted of acetonitrile and water with 0.1% formic acid (Mallinckrodt Baker, Inc., 
Phillipsburg, USA) with a constant flow rate of 0.2 mL/min.  The ratio of water to acetonitrile 
was 1:1 in the absence of the column and 17:3 with the column.  The ion chromatograms of 
sodiated glucose isotopes (m/z 203 for natural glucose and m/z 205 for D-glucose-6,6-d2) were 
selected from the total ion chromatogram using the ChemStation software (Rev. A.06.03 [509]).  
These selected ion chromatograms were integrated to provide peak areas for the two glucose 
signals.  During integration, the software option “baseline hold” was used.  The peak areas of m/z 
203 and 205 were used to determine the glucose-to-D-glucose-6,6-d2 ratio.  When calculating the 
peak area ratio, we took into account the 1.3% m+2 natural isotopic contribution of 
Na+(glucose), m/z 203, to m/z of 205; 1.3% of the observed glucose peak area of m/z 203 was 
subtracted from the observed m/z 205 peak area to determine the area due solely to the internal 
standard.  Each sample was injected three times at 6.5 µL per injection and the average glucose 
concentration recorded.  All human samples were collected through protocols approved by the 
University of Pittsburgh Institutional Review Board. 
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4.4 RESULTS AND DISCUSSION 
The cationization of glucose with H+, Na+, K+, or Pb2+ was examined.  An initial survey 
comparing negative ion to positive ion ESI suggested greater promise with positive ion methods.  
With the exception of sodium, millimolar concentrations of the acid or salt were needed to 
observe the glucose cation adducts as the base peak.  The sodium-glucose adduct was present in 
all of the spectra and in the majority of them was the most abundant ion.  Since sodiated glucose 
dominated even without the addition of sodium and since tear fluid contains ~160 mM of 
sodium52, our glucose analysis is based on the sodiated glucose ion.  Further experiments were 
conducted to ascertain the solvent composition (water, acetonitrile, and methanol) that provided 
the maximum signal for sodiated glucose.  Based on the results of these experiments, a 1:1 ratio 
of water to acetonitrile for the sample solvent was selected.  For the experiments without the use 
of the Nova-Pak C18 column, the 1:1 solvent ratio was also used for the mobile phase with the 
addition of 0.1% formic acid to the aqueous phase to produce more stable baseline ion currents.  
In our initial work, 13C6-glucose was used as an internal standard but an unidentified peak at m/z 
209 (which would interfere with the detection of sodiated 13C6-glucose) was observed in the 
absence of the internal standard.  Therefore, D-glucose-6,6-d2 was a superior alternative since no 
signal was observed at m/z 205 in the absence of the internal standard. 
With the optimal solvents and internal standard established, the effect of the biological 
matrix on the glucose signal was examined.  The sodiated-glucose signal intensity observed for 
both artificial and real tear fluid was low compared to the background signal in our initial studies 
in which samples were directly infused into the mass spectrometer.  Addition of a C18 column 
separated proteins, such as lysozyme, globulin, and albumin, and excess salts from the elution 
time of glucose.  This in-line purification increased both the sensitivity and signal-to-noise ratio 
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for sodiated-glucose.  Analysis of the blank (a protein-free glucose-free artificial tear solution 9) 
showed an average glucose concentration of 0.98 ± 0.56 µM.  With the use of the column the 
statistical limit of detection was lowered to 3 µM.  These improvements occurred in the presence 
of the column with the mobile phase optimized at a solvent ratio of 17:3 of water with 0.1% 
formic acid to acetonitrile which maximized the glucose signal and minimized overlapping 
peaks. 
The precision of the micro-capillaries was measured by gravimetric means.  Five 
individual capillaries were weighed, filled with water at 20oC, and weighed again.  The average 
value for the water contained in the capillaries was 1.008 ± 0.013 mg (1.011 ± 0.013 µL at 20oC).  
Therefore, in all of our analysis of tears we assume a collection volume of 1.00 µL.   
To test the linearity of the method, aqueous solutions with known glucose concentrations 
(0 – 200 µM) were prepared and analyzed.  The linear regression of measured versus added 
glucose gave an equation of y = 0.99 x – 0.78 (R2 = 0.98).  The increase in the relative sodiated 
glucose signal m/z 203 can be easily seen when the mass spectra are normalized to the sodiated 
D-glucose-6,6-d2 signal m/z 205 (Figure 4.1).  
The mass spectral measurement over time of the glucose concentration in the 1:1 ratio of 
water-to-acetonitrile was examined.  A 200 µM glucose aqueous solution was prepared and 
sampled multiple times.  These vials were stored in a refrigerator and tested immediately, a few 
hours later, three days later, and one week later.  The average value for all of the samples was 
201 ± 15 µM with no increasing or decreasing trend over storage time (data not shown).   
The reproducibility of the method was determined with the use of a pooled sample of 
onion-induced tears.  Six samples were collected from the pool and analyzed.  The average 
glucose concentration was 211 ± 8 µM in this stimulated tear sample (data not shown). 
  45
 Figure  4.1:  Eleven spectra of aqueous solutions of known glucose concentrations (0 – 200 µM) with intensities 
normalized to the internal standard D-glucose-6,6-d2 signal intensity at m/z 205.  The linear regression of the 
experimental glucose concentration verses the known glucose concentration provided the best fit equation of 
y = 0.99 x – 0.78 (R2 = 0.98). 
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 Figure  4.2:  Duplicate samples of pooled, induced tears at four different concentrations of added glucose were 
analyzed.  Error bars are plus/minus one standard deviation from the average value of each sample.  Linear 
regression analysis gave an equation of y = 0.99 x + 256 (R2 = 0.99) and a recovery range of 94% to 111% of 
the glucose spike. 
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A recovery experiment was performed on another pooled sample of onion-induced tears.  
The tears were spiked with aqueous glucose solutions to increase the glucose concentration by 0, 
107, 233, and 352 µM.  Linear regression of measured versus added glucose gave an equation of 
y = 0.99 x + 256 (R2 = 0.99) (Figure 4.2).  We also determined that the induced tear fluid 
contained 256 µM glucose. 
The average relative standard deviation over the three 6.5 µL injections of the diluted tear 
samples studied with concentrations greater than 50 µM glucose was 4%.  For the samples 
studied with concentrations less than 50 µM glucose, the average relative standard deviation of 
the three measurements was 15%.  The FDA currently requires self-blood-glucose monitors to 
have an accuracy of within 15%.  Within one standard deviation, the calibration curve is 
indistinguishable from y = x and the recovery experiment shows 100% recovery of added 
glucose.  We therefore feel confident using D-glucose-6,6-d2 as the internal standard and the y = 
x calibration curve to determine tear glucose concentrations. 
We performed two studies on a non-diabetic subject who fasted overnight.  During both 
sessions, which were separated by one week, three samples were taken from each eye.  Samples 
from the same eye were collected at ten minutes intervals.  The tear glucose concentration from 
this subject during the two sessions ranged from 13 to 51 µM with an average of 32 µM (Table 
4.1).  The concentration of tear glucose determined in this work for this non-diabetic subject is 
about four-fold less than the tear glucose concentrations recently reported45.  Whereas previous 
studies used collection methods which either touched the eye or chemically stimulated tears12-14, 
we use glass micro-capillaries to collect a single microliter volume of tear fluid from the tear 
meniscus without touching the eye.  This decrease in reported tear glucose concentration is likely 
due to our less irritating method of tear collection.  The onion-stimulated tears (from a different 
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subject) showed a seven to eight fold higher glucose concentration than in the absence of 
stimulation. 
 
Table  4.1:  Tear Glucose Concentration of a Non-diabetic Subject 
 Session 1 Session 2 
Sample Left Eye Right Eye Left Eye Right Eye 
1st 22 38 44 48 
2nd 51 37 50 25 
3rd 13 17 14 24 
Note:  Concentrations are micromolar. 
 
4.5 CONCLUSION 
In the present study we demonstrate a robust ESI-MS method for determining tear glucose 
concentration in tear fluid.  Liquid chromatography separates glucose from the majority of salts 
and proteins, such as lyzosyme, globulin, and albumin, in tears reducing interference of the 
biological matrix on the sodiated-glucose signal.  The resulting increase in the sensitivity and 
signal-to-noise ratio of glucose over data obtained without the column allows measurements of 
tear glucose concentrations as low as 10 µM (limit of quantification) by relying on an internal 
standard.  We use a 1 µL tear sampling method that is minimally irritating to the eye.  This 
method enables reliable studies of physiological tear glucose concentrations in non-stimulated 
tears.  A preliminary study indicates that the physiological, baseline tear glucose concentration is 
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substantially below previous reports.  Further studies are warranted to determine the inter- and 
intra-individual variation in baseline tear glucose concentration.  This method will be used to 
establish normal values for tear glucose concentration and can monitor changes in tear glucose 
with changes in blood glucose.  Application of this LC-MS method can help us to understand 
tear glucose physiology.  Our future work will determine whether monitoring tear glucose 
concentration is a viable approach for non-invasive blood glucose monitoring.  We are now 
using this method for tear glucose concentration measurements to examine a population of non-
diabetic and diabetic subjects to determine their tear fluid glucose concentrations and their 
correlations of tear glucose with blood glucose.   
4.6 ACKNOWLEDGEMENTS 
The authors thank Kasi Somayajula for his consultation.  This research was supported of the 
National Institutes of Health Grant DK-55348 to Sanford A. Asher. 
  50
5.0  MASS SPECTRAL DETERMINATION OF FASTING TEAR GLUCOSE 
CONCENTRATIONS IN NONDIABETIC VOLUNTEERS 
This work was published as: 
Justin T. Baca, Christopher R. Taormina, David N. Finegold, Joseph J. Grabowski, and 
Sandford A. Asher.  Clinical Chemistry. 2007, 53, 1370.43 
5.1 ABSTRACT 
Background: There is considerable disagreement regarding the concentration of glucose in tears 
and its relationship to the concentration in blood. Improved sampling and analysis methods may 
resolve these discrepancies and possibly provide a basis for in situ tear glucose sensors. 
Methods: We used liquid chromatography (LC) with electrospray ionization mass spectrometry 
(ESI-MS) to determine glucose in 1-µL tear fluid samples obtained from 25 fasting study 
participants. Tear fluid was collected with microcapillaries and a slitlamp microscope. 
Results: The median (range) of fasting tear glucose concentrations was 28 (7–161) µmol/L or 
0.50 (0.13–2.90) mg/dL. The SD of tear glucose measurements for individuals varied linearly 
with the mean tear glucose concentration and was approximately half of the mean. We found no 
significant difference in tear glucose concentrations between contact lens users and nonusers (P 
= 0.715). We observed significant correlations between fasting blood and tear glucose 
concentrations (R = 0.50, P = 0.01). 
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Conclusions: Our tear fluid collection and analysis method enables reliable measurement of 
equilibrium, fasting tear glucose concentrations. These concentrations are lower than those 
previously reported for nondiabetic persons. Larger population studies are required to determine 
correlations between blood and tear glucose concentrations and to determine the utility of contact 
lens–based sensors for the monitoring of diabetes.  Our methods are applicable for study of other 
tear fluid analytes and may prove useful for monitoring other disease states. 
5.2 RESULTS AND DISCUSSION  
Glucose has been a recognized component of tear fluid since the early 1900s, but disagreement 
continues regarding its concentration in tear fluid and its correlation with blood glucose 
concentration.12,44,48,66-68  Literature reports of normal tear glucose concentrations range between 
0 and 9.1 mmol/L (164 mg/dL), with median values of 110–280 µmol/L (1.98 and 5.04 
mg/dL).12,46  In a recent study of 121 persons, tear glucose concentrations ranged from below the 
limit of detection to 9.1 mmol/L (164 mg/dL).46  Much of the difference in reported tear glucose 
concentrations is likely from the use of different tear collection techniques.13  Collection 
techniques causing severe eye irritation such as filter paper collection68 are associated with the 
highest tear glucose concentrations, whereas less irritating techniques (such as glass capillary 
collection) are associated with the lowest.44,48  Chemically stimulated tears have increased tear 
glucose.13,42  Reliable tear sampling may also be confounded by individual differences in 
tolerance to real or expected eye stimulation during sampling.  
Improved tear fluid collection, and the ability to analyze very low volumes of tear fluid, 
may dramatically improve measurement of tear fluid glucose concentrations and help resolve the 
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reported discrepancies in basal tear glucose concentrations.  Improved methods would also 
enable the study of physiologic glucose transport in the eye and advance the use of tear fluid as a 
surrogate for blood in measuring other clinically important analytes.   
Some groups have tried to use tear glucose to diagnose diabetes66,67, and others have 
proposed continuous monitoring of blood glucose concentrations by use of contact lenses with 
glucose sensors.9,11,69,70  We recently reported a photonic crystal glucose-sensing material for 
noninvasive monitoring of glucose in tear fluid.9  Detailed understanding of tear glucose 
concentration and its regulation is critical to developing noninvasive glucose sensors.   
We recently developed an electrospray ionization mass spectrometry (ESI-MS) method 
for measuring glucose in 1-µL samples of collected tear fluid.42  With this method, we studied 
basal tear glucose concentrations in healthy persons without diabetes.   
We recruited volunteers (age 18–60 years) within and around the University of 
Pittsburgh. Persons with a history of diabetes were excluded.  Blood and tear samples were 
obtained after participants had fasted overnight for at least 8 h.  The samples were always 
collected in the same order: capillary blood from the finger pad, tear fluid from the left eye, and 
then tear fluid from the right eye.  This sequence was repeated 3 times for each study participant, 
with at least 10 min between successive blood sample collections.  Glucose in capillary blood 
was measured with an Accu-Chek® Compact glucometer (Roche), according to the 
manufacturer’s protocol.   
A total of 26 volunteers completed the study; 11 wore their usual contact lenses at the 
time of the study, and 15 did not wear contact lenses.  The type of contact lenses worn were daily 
disposable (n = 1), daily wear (n = 6), extended wear (n = 1), and silicone hydrogel lenses (n = 
2).  Of the 15 non-contact lens wearers, 1 had a history of contact lens use, but did not wear 
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contacts on the day of the study.  For 1 contact lens wearer, the collected tear samples were lost 
because of vial breakage before analysis.  For 2 participants (1 from the contact lens group and 1 
from the non-contact lens group), 1 of the 6 tear glucose samples was lost because of instrument 
failure.  The tear glucose concentration statistics for these 2 participants were determined from 
only 5 samples.  The University of Pittsburgh School of Medicine Institutional Review Board 
approved all clinical procedures, and all participants signed a detailed informed consent form. 
Tear fluid samples of 1 µL were collected and analyzed by liquid chromatography ESI-
MS as previously reported.42  Three aliquots of each tear sample were injected into the analyzer 
to determine the mean glucose concentration.  Our study found much lower tear fluid glucose 
concentrations for healthy individuals than did previous studies (Figure 5.1). 
The population median (range) of the tear glucose concentrations were 28 (7–161) 
µmol/L [0.50 (0.13–2.90) mg/dL]. The distribution of mean tear glucose concentrations was 
highly skewed; <28 µmol/L (0.50 mg/dL) in 50% of the study participants and <42 µmol/L (0.76 
mg/dL) in 80% of the study participants.  Two individuals were observed rubbing their eyes 
during the course of the study, and they had the highest mean (SD) tear glucose concentrations: 
128 (75) and 161 (71) µmol/L or 2.31 (1.35) and 2.90 (1.28) mg/dL. 
Because the SD of the mean tear glucose concentration for each participant was 
proportional to the mean for each participant, a natural log transformation was applied to the tear 
glucose concentration values (Figures 5.2 and 5.3).  After transformation, standard statistical 
methods were applied.   
Contact lens use did not affect mean tear glucose (P = 0.715).  Transformed tear glucose 
concentrations were significantly correlated with mean blood glucose (R = 0.50, P = 0.01, Figure 
5.4A).  This correlation for fasting tear and blood glucose is similar to that reported by Daum 
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Figure  5.1:  The six tear glucose concentrations determined for each subject are plotted against the subject’s 
average blood glucose concentration.  All tear glucose measurement for a given subject are in vertical 
alignment.  Large variations occur in the value of the tear glucose concentrations for each subject between 
their eyes and between subsequent measurements of each eye over the course of the study (30-40 minutes).  It 
should be noted that in all cases blood glucose concentration remains essentially constant over the 
measurement interval as subjects had fasted overnight. 
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Figure  5.2:  The standard deviations of the six tear fluid glucose measurements for each subject are linearly 
proportional to the mean value measured (~50% of the mean value). 
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Figure  5.3:  The transformed tear glucose values of the six tear glucose determinations for all subjects are 
plotted against the subject’s average blood glucose concentration.  There is significant variation in the tear 
glucose concentration measured in individual subjects over the course of the study (30-40 minutes).  Note that 
all tear glucose measurements for a given subject are in vertical alignment.  The average natural log 
transformed tear glucose value for non-contact-wearing subjects was 3.1 ± 0.8, and 3.2 ± 0.8 for contact-
wearing subjects (mean ± SD). 
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 Figure  5.4:  (A) Correlation (P = 0.01) between the mean ln(tear glucose concentration) and the mean blood 
glucose concentration.  A linear regression for all participants gives y = 0.80x – 1.07 (R = 0.50). (B) Linear 
regression for the subpopulations of contact wearers and non-contact wearers gives y = 0.570x + 0.332 (R = 
0.22) for contact lens wearers and y = 0.961x – 2.079 (R = 0.70) for non-contact wearers. No significant 
differences were observed between right and left eyes (P = 0.76, two-tailed paired t-test), but results may 
differ at any given time. The left and right tear glucose determinations that are closest in time are plotted 
against each other. There are hence 3 data points for each study participant. 
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and Hill of R = 0.53 for blood and tear glucose measurement variations throughout the day.  
However, they reported a mean (SD) population tear fluid glucose concentration of 420 (355) 
µmol/L or 7.57 (6.40) mg/dL. 
The glucose concentrations in the right and left eyes were highly correlated within 
individuals (Figure 5.4B).  There was no evidence that eye-to-eye variation in individual study 
participants differed significantly from variation in a single eye over time.  Furthermore, we 
observed no evidence that variation in tear glucose concentration between individuals with 
similar blood glucose concentrations was greater than variation in tear glucose concentration 
within an individual.  
The correlation between the transformed tear glucose value and the average blood 
glucose concentration appears to be stronger for non-contact lens wearers than for participants 
wearing contact lenses (R = 0.70 vs R = 0.22).  However, analysis of covariance does not 
indicate a significant difference (P = 0.63). 
The ESI-MS method used here enables reliable determination of basal tear glucose 
concentrations in fasting individuals.  Study participants had fasted overnight, and had stable 
blood glucose concentrations over the brief course of the study.  We observed much lower basal 
tear glucose concentrations than previously reported for healthy individuals.  This difference is 
likely a result of our sampling methods, which were less irritating than earlier methods that 
stimulated tear production chemically or with filter paper.13  If our collection method had caused 
significant irritation, we would have expected tear glucose concentrations to increase over the 
course of the study.   
We observed no evidence of such an increase (Figure 5.5).  We observed significant 
variation in tear glucose concentrations between the 2 eyes of individual study participants, as 
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Figure  5.5:  A plot of the relative difference in tear glucose concentration from the average tear glucose value 
for each subject versus time does not show a significant trend.  If the sampling procedure caused significant 
irritation to the eye, we would expect an overall relative increase in tear glucose concentration with time. 
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well as over time within a single eye.  During this study, we were cognizant of potential 
confounding events such as yawning and eye rubbing.  Although the 2 individuals who rubbed 
their eyes during the study had the highest glucose concentrations, events like these do not 
explain the large within-individual differences observed. 
Variations in tear glucose concentrations within a single individual must derive from the 
sum of the biological variance and any variances associated with sampling and measurement.  
The error in our tear fluid collection volumes was negligible42; the SD observed for an individual 
was <3 times the SD of the 3 replicate mass spectral measurements of a single tear fluid sample. 
The relative SDs of these 3 replicates varied somewhat with glucose concentration but had a 
median value of 14%. Thus, the observed SD in tear glucose measurements derive mainly from 
actual variations of the glucose concentration in the different tear fluid samples. 
We did not observe a systematic increase over time in glucose concentration variations 
that could result from the effect of tear depletion during repeated measurements.  Tear glucose 
concentration appeared to vary randomly over the repeated sampling events. 
We observed variations in tear glucose concentrations among fasting individuals and a 
significant correlation between ln(tear glucose concentration) and blood glucose concentration.  
Mean fasting tear glucose concentrations did not differ significantly in relation to contact lens 
use.  Further studies are needed to investigate the apparent difference in the correlation between 
tear glucose and blood in these subpopulations.   
The extremely low glucose concentrations in tear fluid, more than 100 times lower than 
in blood, raise questions about the physiologic role of tear glucose. Future studies are needed to 
address the correlation between tear and blood glucose in hypoglycemic and hyperglycemic 
states and in the presence of diabetes. 
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6.0  PEPTIDES 
Neuropeptides are a diverse class of inter-neuron-signaling molecules which participate in 
various physiological functions.5,15-17  Direct analysis of the neuropeptide content of a biological 
fluid would prove invaluable to the understanding of neurological functions.  In conjunction with 
Dr. Michael’s group, this study analyzes interstitial fluid adjacent to unharmed cells in the brain 
of a rat.  Previous studies have used microdialysis to collect samples in vivo.5,18  The large size 
of the microdialysis probe relative to the rat brain has been shown to damage cells upon 
insertion.19  The damaged cells could alter the concentrations of neuropeptides in the interstitial 
fluid through the exposure of the cell’s interior.  To minimize the damage to the brain, smaller 
tapered fused silica capillaries instead of a microdialysis probes can be used to sample fluid.  The 
ESI-MS based analysis of these samples is ideal due to the small volume and low concentrations. 
 
6.1 EXPERIMENTAL 
The experiments were conducted with the instrumentation described in Chapter 2.4.  The 
peptides and chemicals were purchased from Sigma Chemical Company (St. Louis, MO).  They 
were dissolved in water and then co-solvent (methanol or acetonitrile) and the acid or base were 
added.  All of the enkephalin standards were sprayed from a New Objective capillary tip with an 
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orifice of 10 µm with 2.0 kV applied to the spray tip and with a flow rate of 100 nL/min set on 
the syringe pump.  Data were collected for five minutes and all scans were averaged to provide 
the spectra. 
The dynorphin standards for the HP LCMS were dissolved in water (10 µM) and injected 
directly into the solvent flow of 60% water containing 1% acetic acid and 40% acetonitrile.  The 
instrument used a flow rate of 400 µL/min and 3.0 kV applied to the spray tip.  The dynorphin 
standards for the SWISS-484 were dissolved in water (10 µM) and diluted to provide a 1% acetic 
acid and 50% methanol solution.  The solutions were sprayed from a New Objective tip with a 
15 µm orifice with 3.0 kV applied and at a flow rate of 300 nL/min. 
The CID experiments were performed with a pressure of 3x10-5 Torr of argon gas.  The 
pole biases of the octopole and Q3 were set at -20V and -30V respectively.  The experiments 
with the sodiated leucine-enkephalin differed from this only in that the pole biases were set to 
-10V and -15V respectively for higher resolution spectra. 
The experiments with the rat brain fluid also followed the general procedure as stated in 
Chapter 2.4.  The rat brain was infused with the standard for one hour at a rate of 100 nL/min (6 
µL volume total injected).  Once the hour passed the collection of the fluid began and lasted an 
hour at a rate of 7 nL/min (0.42 µL volume total collected).  The samples contained in the fused 
silica capillaries were attached to a PEEK connector and sprayed through a New Objective tip 
with a 10 µm orifice.  A flow rate of 50 nL/min was applied to the solution with a syringe pump 
and 2.0 kV was applied on the tip.  For the CID experiments for the rat brain experiments had 
pressures in the CID chamber and voltages of the pole biases of 3x10-5 Torr, 
-20V (O), and -25V (Q3) or 5x10-5 Torr, -10V (O), and -15V (Q3).  
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6.2 PEPTIDE CHARACTERIZATION 
To assess the abilities of the SWISS-484, the spectra of known peptide solutions were acquired.  
The majority of the tests of these solutions dealt with the constituents of the solvent.  
Experiments were performed on leu-enkephalin, met-enkephalin, dynorphin A, and dynorphin B.  
The ideal conditions to obtain spectra for identification generally were found to consist of a 
micromolar peptide concentration, a solvent containing 25-50% organic co-solvent (i.e., 
methanol or acetonitrile), and addition of acid to promote protonation in the spray process.  If 
sodium ions are in the solution the sodiated ion will appear in the spectra and at the expense of 
the signal of the protonated ion.  Millimolar concentrations of salt in the solution or lack of a co-
solvent adversely affects the ion signal by yielding an assortment of cluster ions and a 
significantly smaller signal-to-noise ratio for any individual peak. 
A second goal of the characterization studies was to optimize the collision induced 
dissociation (CID) parameters for quantitation experiments.  These experiments were performed 
on the enkephalins and the dynorphins.  The protonated ions of the peptides produced typical 
product ions in the form of Roepstorff’s nomenclature (y2, b3, a2).71  The sodiated ions showed 
rather high specificity in accord with previous work by Westmore72 and Beauchamp.34  The 
unique fragmentation of each peptide can be used to enhance quantitation through increased 
signal-to-noise and ion selectivity.  Selected ion monitoring (SIM), multiple ion monitoring 
(MIM), and selected reaction monitoring (SRM) can be used toward this end.  All three of these 
methods are utilized to determine the best route to quantify neuropeptides in interstitial brain 
fluid. 
  65
6.2.1 Solvent Effects 
Leucine-enkephalin and methionine-enkephalin are pentapeptides and differ only in their C-
terminal amino acid.  Leucine-enkephalin (LEnk) has the N to C sequence of tyrosine-glycine-
glycine-phenylalanine-leucine and the mono-isotopic molecular weight of 555.3 Daltons.  
Methionine-enkephalin (MEnk) has the N-to-C sequence of tyrosine-glycine-glycine-
phenylalanine-methionine and the mono-isotopic molecular weight of 573.2 Daltons.  Spectra 
were first taken with the SWISS-484 with micromolar concentrations of the peptides in 100% 
water.  Direct injections into the mass spectrometer were made without any modifications to the 
solutions.  In these spectra the protonated species (MW + 1) is the most intense ion, 556.3 
Daltons for LEnk and 574.2 Daltons for MEnk (Figure 6.1).  Along with these peaks are the 
sodiated ion (MW + 23) and the substitution of a sodium for a proton to the sodiated ion (MW – 
1 + 46).  These additional peaks show that the solutions were not devoid of all salt ions.     
The addition of an organic co-solvent of methanol or acetonitrile and acid proved to 
enhance the overall intensity of the peaks, especially the protonated species (Figure 6.2a).  
Further experiments with the organic solvent showed that adding approximately 1% acid and 10 
to 50% by volume organic co-solvent to obtained the best signal-to-noise ratio of a protonated 
ion.  The addition of salt to the solution typically provides a spectrum with the corresponding 
analyte-salt cation adduct as shown in Figure 6.2b.  With artificial cerebrospinal fluid (aCSF, 
Table 6.1) as the solvent, the high concentration of sodium ions depletes the protonated species, 
promotes the sodiated species to the most intense ion, and causes the additional substitution of 
sodium ions for protons on the molecule.  The use of certain salts in electrospray ionization 
solutions results in aggregates that can overwhelm the analyte peaks.  The addition of 20 µM of 
sodium acetate to the solution provides spectra (Figure 6.2c) only with the salt cluster peaks
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Figure  6.1:  Spectra of (a) 63 µM leucine-enkephalin and (b) 300 µM methionine-enkephalin in water 
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Figure  6.2:  Solvent dependence of spectra with leucine-enkephalin in (a) 13% methanol and 1% acid (55 µM 
LEnk), (b) 100% aCSF (63 µM LEnk), and (c) 20 µM sodium acetate (10 µM LEnk, n signifies the number of 
sodium acetates in the sodiated sodium acetate cluster, LEnk was not observed). 
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Table  6.1:  Ion content of aCSF 
Salt ion Concentration in aqueous solution (mM) 
Sodium 147.3 
Calcium 1.6 
Potassium 2.7 
Chloride 150.9 
Magnesium 2.1 
Phosphate buffer 2.3 
with pH adjusted to 7.4 with sodium hydroxide 
 
 (CH3COONa)nNa+ where 2 < n < 8.  The elimination of salts from solutions prior to ESI-MS 
analysis would be beneficial for the observance of the protonated analyte.  One way to remove 
salts from a sample is with the use of Millipore’s Ziptips, which are essentially small 
chromatography columns.  Following the procedure provided by Millipore, ESI-MS solutions 
can be produced where the majority of the peptides are protonated rather than sodiated.  For 
example a sample of 10 µM LEnk in aCSF gives a spectrum (Figure 6.3a) with different cationic 
species of leucine-enkephalin and a poor signal-to-noise ratio.  After the use of a Ziptip, the 
solution provides a spectrum (Figure 6.3b) with increased signal-to-noise ratio of the protonated 
peak.   
Another neuropeptide dynorphin A (2147.53 Daltons) is a heptadeca-peptide with the N 
to C sequence of YGGFLRRIRPKLKWDNQ in single letter amino acid format.  In the spectra 
obtained on the commercial HP LC-MS instrument the double, triple, and quadruple charged 
ions are seen (Figure 6.4a) whereas on the SWISS-484 only the triply and quadruply charged 
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Figure  6.3:  Spectra of 10 µM leucine-enkephalin in 100% aCSF (a) before use of Ziptip and (b) after use of 
Ziptip (50% methanol and 1% acetic acid). 
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Figure  6.4:  Spectra of dynorphin A obtained on the (a) HP LC-MS (10 µM) and the (b) SWISS-484 (5 µM). 
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molecule appear (Figure 6.4b).  This difference is likely due to a difference in the addition of 
acid.  With the HP LCMS, acid was not added to the peptide solution but was in the mobile 
phase, while the experiment with the SWISS-484 was a direct injection of a solution with 1% by 
volume of acetic acid added.  The abundance of acid in the latter will lower the pH and provide 
more protons to increase the charge on the molecule. 
6.2.2 Collision Induced Dissociation 
The SWISS-484 has a triple multipole setup with the octopole acting as a collision cell allowing 
the obtainment of ion structure information through collision induced dissociation (CID).  
Figures 4.5 and 4.6 show the CID spectra of protonated leucine-enkephalin and protonated 
methionine-enkephalin respectively.  In the case of peptides, Roepstorff’s nomenclature71 is the 
generally accepted guide for ease of fragment ion identification.  The A, B, and C fragment ions 
contain the N-terminal side of the parent peptide and the X, Y, and Z fragment ions contain the 
C-terminal side.  The protonated enkephalins fragment readily with the collision cell at a 
pressure of 3x10-5 Torr of argon gas.   The A4 and B4 ions are the most abundant of the 
fragments which is in agreement with the literature.72  As shown by Beauchamp34 the sodiated 
peptide ions have a specific fragmentation pathway.  The ions sequentially fragment down the 
amino acid bonds starting at the C-terminal.  A single collision of sodiated methionine-
enkephalin with a neutral produces m/z 465.2 and a second collision with the fragment ion and a 
neutral will provide m/z 318.1 (Figure 4.7).  With a single spectrum containing the protonated 
and sodiated ions, subsequent MIM and SRM can be performed on both ions in the same scan 
showing the difference in fragmentation.  In the case of an unknown peptide, the fragmentation 
can ease the interpretation of the ion’s sequence and structural aspects. 
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Figure  6.5:  Collision induced dissociation of protonated leucine-enkephalin (LEnk) sprayed from a solution 
of 18 µM LEnk in 75:25 methanol:water with 1% acetic acid.  The list on the left represents all of the possible 
A, B, C, X, Y, and Z fragments.  The structure on top is LEnk with the observed fragments.  Each vertical 
line with an arrow indicates the protonated peptide fragment that is observed (i.e., B5 is the protonated 
peptide without the C-terminal end OH group).  The spectrum is the CID of LEnk with each fragment 
labeled.  An asterisk (*) indicates a loss of NH3 from that particular fragment. 
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Figure  6.6:  Collision induced dissociation of protonated methionine-enkephalin (MEnk) sprayed from a 
solution of 92 µM MEnk in 75:25 methanol:water with 1% acetic acid.  The list on the left represents all of 
the possible A, B, C, X, Y, and Z fragments.  The structure on top is MEnk with the observed fragments.  
Each vertical line with an arrow indicates the protonated peptide fragment that is observed (i.e., B5 is the 
protonated peptide without the C-terminal end OH group).  The spectrum is the CID of MEnk with each 
fragment labeled.  An asterisk (*) indicates a loss of NH3 from that particular fragment. 
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Figure  6.7:  Collision induced dissociation of sodiated methionine-enkephalin (MEnk) 
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6.2.3 Internal Standard Calibration Curves 
The main goal in the neuropeptide project is to quantitate peptides within biological fluids.  It 
has been demonstrated that the most reliable calibration curve results from an internal 
standard.2,39,53  The internal standard should be a molecule similar to the analyte being examined.  
An isotopically-labeled version of the analyte is often used to fulfill the internal standard 
criteria.2,53   
As a test for reproducibility, methionine-enkephalin was used as the analyte and leucine-
enkephalin was used as the internal standard.  Solutions were made containing 16 µM of LEnk 
and 0.72 µM to 72 µM of MEnk in 49.5% water, 49.5% methanol, and 1% acetic acid.  For each 
solution, three five-minute spectra were collected (Q1 scan, Q3 scan, and MIM scan of the two 
protonated enkephalins). The spectra were averaged and the heights of the protonated ions were 
plotted with and without the use of the internal standard (Figure 4.9).  The curves show the use 
of the internal standard increases the reliability of the linear regression.  Out of the three methods 
of collecting data, the Q3 scan has the best linear fit (R2 = 0.9843).  Combining the linear fit with 
sensitivity, indicated by the slope, the Q3 scanning of the ions would be the most accurate 
method.   
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Figure  6.8:  Calibration curve of (a) methionine-enkephalin abundance and (b) methionine-enkephalin 
abundance to leucine-enkephalin abundance ratio.  The standard addition of leucine-enkephalin was at a 
concentration of 16 µM and the methionine-enkephalin concentration ranged from 0.72 µM to 72 µM. 
  77
6.3 BIOLOGICAL SAMPLES 
Experiments were done on interstitial brain fluid of a rat obtained with a unique technique of 
collecting samples from the interstial fluid of the brain.  A fused silica capillary with ID of 25 
µm was tapered down to a thin OD wall at the tip of the capillary.  These tips were then 
delicately placed into the surgically exposed brain tissue of the rat.  The other end of the 
capillary was then connected to a syringe pump.  Two of these capillaries were placed into the 
brain.  One capillary was used to inject a known concentration of analyte at a rate of 100 nL/min 
and the second capillary was used to pull fluid at a rate of 7 nL/min.  In these experiments, LEnk 
(YGGFL) or GGFL in aCSF solution were used as the injected analyte.  After a collection time 
of 60 minutes the capillaries containing fluid were removed from the rat and were brought to the 
mass spectrometer.  After removing the tapered capillary tip (necessary to ensure a good seal), 
the capillary was attached to a New Objective tip with a PEEK union.  Each experiment 
progressed through a Q3 scan to SIM of the sodiated LEnk m/z 578 to CID of the sodiated LEnk 
m/z 578 and finally to SRM of the known fragment of sodiated LEnk m/z 465.  The first two 
steps of the progression were initiated by a successful observation of m/z 578 in the spectra.  A 
lack of 2-to-1 signal-to-noise ratio prompted the switch from CID to an SRM experiment to 
verify the m/z 578 peak as sodiated LEnk. 
Through the course of these experiments, spectra were obtained in 11 of the 22 
experiments.  Failure to obtain spectra was due to either the lack of fluid uptake into the capillary 
or the failure to initiate the spray process.  Scanning Q3 showed many peaks but only the m/z 
corresponding to the sodiated analyte could be seen as confirmation of the injected analyte in the 
collected sample.  However, performing SIM, CID, and SRM on the m/z value did not provide a 
stable intensity for the selected ion or fragment ions.  The correct fragment ion intermittingly 
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would be obtained for the analyte during CID and SRM but would quickly disappear.  These 
inconsistencies in the data must be solved before the method can progress toward quantification. 
One possibility to obtain consistent data is to separate the analyte from the other 
constituents of the sample.  The high salt content in the samples will decrease the sensitivity of 
the method by the spread of ions and suppression of the electrospray as described in Chapter 3.  
Modifications to the capillary by creating a liquid chromatography-mass spectrometry system 
similar to Kennedy’s instrumentation5 should increase the probability of detection.  The 
concentration and desalting of the analyte should enable the sensitivity to be increased and 
provide signal stability and more consistent data. 
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7.0  PROTEINS 
There are hundreds of thousands of proteins expressed in the human brain alone.  Many 
questions still remain on how all of these proteins originate form a much smaller set (~30,000) of 
proton coding genes.73  A large amount of this diversity of gene expression is created by the 
splicing event, which is yet to be fully understood.20  Polypyrimidine-tract-binding proteins 
(PTB) and neuroblastoma apoptosis-related protein (NAPOR) have been identified to have a role 
in the splicing mechanisms.20,21  With the use of ESI-MS, these proteins’ structural aspects 
important to splicing functions can be explored. 
Proteins analyzed with ESI-MS are typically observed with multiple charges on them.  
The “envelope” of charges can be deconvoluted to provide a molecular weight for the protein 
without any charges.  The proteins’ amino acid sequence can be identified through a combination 
of digestion and collision-induced-dissociation (CID).74  Also, the protein-RNA complex can be 
explored with the “soft ionizaton” of electrospray ionization which allows non-covalent binding 
to be transferred to the gas phase.75   
In this study, well-documented proteins are explored on two electrospray-ionization mass 
spectrometers.  These experiments facilitated the optimization of the instruments’ parameters for 
protein analysis.  The lesser known proteins, PTB and NAPOR, along with RNA are analyzed 
individually and in complexes with each other. 
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7.1 EXPERIMENTAL 
The characterization proteins were obtained from Sigma Chemical Company (St. Louis, MO) 
and the neuroproteins were obtained from Dr. Paula Grabowski’s group.  The experiments 
performed on the HP LCMS were direct injections into the “mobile phase” flowing directly into 
the mass spectrometer.  The injections were 1 µL in volume with the exception of the 5 µL 
injections in the PTB experiments.  The solutions of standard proteins contained only water prior 
to the mixing with the “mobile phase” with the exception of pepsin which had 1% ammonium 
hydroxide added.  The solutions of the neuroproteins and RNA had the 1% acetic acid or 1% 
ammonium hydroxide added prior to injection.  The flow rate of the “mobile phase” was 0.4 
mL/min.  The “mobile phases” for the BSA, CA, and RNA experiments were water containing 
0.1% triflouroacetic acid, 60% water containing 1% of acetic acid and 40% acetonitrile, and 60% 
water and 40% acetonitrile respectively.  The experiments performed on the SWISS-484 were all 
direct injections under conditions stated previously in the SWISS-484 section.  The flow rate for 
the experiments was 300 nL/min.  For carbonic anhydrase, a 26 µM, 1% acetic acid, and 25% 
methanol aqueous solution was used with 3.0 kV applied to the tip with a 10 µm orifice.  For 
cytochrome c, a 70 µM aqueous solution was used with 3.0 kV applied to the tip with a 10 µm 
orifice.  For myoglobin, a 4.5 µM, 1% acetic acid, and 25% methanol aqueous solution was used 
with 2.0 kV applied to the tip with a 15 µm orifice.  For NAPOR, a 5 µM, 1% acetic acid, 50% 
methanol, and 50% ammonium acetate solution was used with 2.0 kV applied to the tip with a 15 
µM orifice. 
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7.2 CHARACTERIZATION PROTEINS 
As with peptides, known solutions of proteins are used to characterize the capabilities of the 
SWISS-484.  Cytochrome C, myoglobin, carbonic anhydrase II (CA), pepsin, and bovine serum 
albumin (BSA) were used to this end.  These proteins range in molecular weight from 12 
kiloDaltons to 67 kiloDaltons.  Micromolar protein concentrations in a solution with 10-50% co-
solvent and ~1% acid or base provided the best signal-to-noise ratios.  The spectra of CA, 
pepsin, and BSA were also obtained from the HP LC-MS in order to compare the two 
instruments.  Experiments with CA were performed under positive ion conditions and produced 
an envelope with a range of 20 to 40 charges (Figure 5.1a).  Experiments with Pepsin were 
performed under negative ion conditions and produced an envelope with a range of 25 to 42 
charges (Figure 5.2).76  Experiments with BSA were performed under positive ion conditions and 
produced an envelope with a range of 35 to 60 charges (Figure 5.3) as in the literature.77  Among 
other things, these three experiments demonstrate that the larger the protein is, the greater the 
number of charges it can accommodate.  Using MagTran to deconvolute the envelope of peaks, 
the average MW of the parent ion was less than a tenth of a percent different from the expected 
value.  The spectra of cytochrome C (Figure 5.4), myoglobin (Figure 5.5), and CA (Figure 5.1b) 
were obtained using the SWISS-484. All three experiments were performed in the positive ion 
mode.  The spectra had charge ranges of 7-14 for cytochrome C, 12-25 for myoglobin, and 20-35 
for CA.  All of these spectra are consistent with spectra found in the literature.78  The percent 
difference from the assigned protein’s MW to the known value is greater, around 1%, in the 
SWISS-484 data than in the HP data.  However, the obtained spectra give an indication of the 
SWISS-484’s capabilities for viewing the molecular weights of proteins.   
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(b)
 
 
Figure  7.1:  Spectra of carbonic anhydrase II obtained on the (a) HP LCMS (34 µM) and the (b) SWISS-484 
(26 µM) each deconvoluted by MagTran.  The lower spectra for each experiment are the raw data with letters 
(A, B, C …) signifying an “envelope” and numbers (15, 16, 17 …) signifying the number of protons on the 
structure.  The upper spectrum for each experiment is the deconvoluted output showing the molecular weight 
each “envelope” represents.  The intensity of each molecular weight provides the total abundance of the 
“envelope”.  MagTran was only able to find one “envelope” in the spectrum from the SWISS-484 so there are 
no letters associated with the charges. 
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MagTran:  34,511 amu
Known:     34,497 amu
% difference:  0.04%
 
 
Figure  7.2:  Spectrum of 58 µM pepsin in 1% NH4OH obtained from the HP LCMS and deconvoluted by 
MagTran.  The lower spectrum is the raw data with letters (A, B, C …) signifying an “envelope” and 
numbers (20, 21, 22 …) signifying the number of protons missing from the structure.  The upper spectrum 
for each experiment is the deconvoluted output showing the molecular weight each “envelope” represents.  
The intensity of each molecular weight provides the total abundance of the “envelope”. 
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MagTran:  66,421 amu
Known:     66,437 amu
% difference:  0.02%
 
 
Figure  7.3:  Spectrum of 45 µM bovine serum albumin obtained from the HP LCMS and deconvoluted by 
MagTran.  The lower spectrum is the raw data with letters (A, B, C …) signifying an “envelope” and 
numbers (42, 43, 44 …) signifying the number of protons on the structure.  The upper spectrum for each 
experiment is the deconvoluted output showing the molecular weight each “envelope” represents.  The 
intensity of each molecular weight provides the total abundance of the “envelope”. 
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MagTran:  12,524.8 amu
Known:     11,820.4 amu
% difference:  5.96%
 
 
Figure  7.4:  Spectrum of 70 µM horse heart cytochrome C in water obtained from the SWISS-484 and 
deconvoluted by MagTran.  The lower spectrum is the raw data with numbers (10, 11, 12 …) signifying the 
number of protons on the structure.  The upper spectrum for each experiment is the deconvoluted output 
showing the molecular weight each “envelope” represents.  The intensity of each molecular weight provides 
the total abundance of the “envelope”.  MagTran was only able to find one “envelope” in the spectrum so 
there are no letters associated with the charges. 
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MagTran:  16,973.3 amu
Known:     16,951.4 amu
% difference:  0.13%
 
 
Figure  7.5:  Spectrum of 4.5 µM myoglobin in 25:75 methanol:water with 1% acetic acid obtained from 
SWISS-484 and deconvoluted by MagTran.  The lower spectrum is the raw data with letters (A, B, C …) 
signifying an “envelope” and numbers (15, 16, 17 …) signifying the number of protons on the structure.  The 
upper spectrum for each experiment is the deconvoluted output showing the molecular weight each 
“envelope” represents.  The intensity of each molecular weight provides the total abundance of the 
“envelope”.   
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7.3 BACTERIALLY GROWN PROTEINS 
Most of the work on the unknown samples has been performed on the HP LC-MS.  Samples of 
polypyrimidine tract binding (PTB) A1 and A2 proteins and neuroblastoma apoptosis-related 
(NAPOR) protein have been tested.  The samples were first received in TRIS buffer.  The 
presence of TRIS proved to be fatal to the MS analysis of the proteins (including with the 
commercial instrument).  The solution was dialyzed to remove TRIS and reanalyzed.  Both PTBs 
provided spectra with a wide range of charge (z) values (Figure 5.6).  The deconvolution gave a 
molecular weight with a mass percent difference from the expected value of less than 5%.  The 
spectra of NAPOR is poorly resolved (Figure 5.7a) compared to the reference proteins examined.  
The most abundant molecular weight does match the predicted molecular weight of the protein 
with a high accuracy, 0.06% mass difference.  NAPOR was examined on the SWISS-484 but an 
envelope of ions was not obtained (Figure 5.7b).  These spectra provide only a small amount of 
data for the protein; CID must be performed to complete the structural analysis.   
The CID process would be more helpful if the protein is digested into smaller fragments 
before collision induced dissociation.  Without digestion the intact protein would require a high 
collision energy to provide a good spectrum of fragments.  Even with efficient fragmentation, the 
spectrum would have a large number of peaks.  In such a case, overlapping and poor signal-to-
noise ratios would likely combine to make the spectrum indecipherable.  Digesting the proteins 
will provide peptides that can be separately identified by CID.  With the amino acid sequence of 
the peptides known, the protein sequence can be pieced back together.   
A seventeen nucleotide RNA known to bind to these neuroproteins was obtained from 
Dr. Paula Grabowski’s group.  An additional goal was to determine the extent of complexation 
of PTB and NAPOR proteins with that RNA molecule.  Since RNA is a highly negative charged 
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structure, the use of negative ion mode is regarded as the ideal route79.  At present negative ion 
spectra of proteins have only been obtained on the HP LC-MS.  The spectra of the RNA were 
acquired in the negative ion mode (Figure 5.8).  To date, MS observation of the complex 
between the RNA and proteins has not been successful. 
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M a g T r a n :   6 1 , 8 5 1  a m u
K n o w n :      5 9 , 3 3 5  a m u
%  d i f f e r e n c e :   4 . 2 4 %
M a g T r a n :   5 9 , 3 6 6  a m u
K n o w n :      5 6 , 9 3 7  a m u
%  d i f f e r e n c e :   4 . 2 7 %
(a)
(b)
 
 
Figure  7.6:  Spectra of 10 µM polypyrimidine tract binding proteins, (a) PTB A1 and (b) PTB A2, in 1% 
acetic acid obtained form the HP LCMS and deconvoluted by MagTran.  The lower spectra for each protein 
are the raw data with letters (A, B, C …) signifying an “envelope” and numbers (70, 71, 72 …) signifying the 
number of protons on the structure.  The upper spectrum for each experiment is the deconvoluted output 
showing the molecular weight each “envelope” represents.  The intensity of each molecular weight provides 
the total abundance of the “envelope”.   
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Figure  7.7:  Spectra of NAPOR obtained from (a) HP LCMS (10 µM) and deconvoluted by MagTran and (b) 
SWISS-484 (5 µM) which MagTran was unable to deconvolute. 
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MagTran:  7,030.4 amu
Known:     7,037.1 amu
% difference:  0.10%
 
 
Figure  7.8:  Spectra of the 64 µM seventeen nucleotide RNA obtained from the HP LCMS and deconvoluted 
by MagTran.  The lower spectrum is the raw data with letters (A, B, C …) signifying an “envelope” and 
numbers (8, 9, 10 …) signifying the number of protons missing from the structure.  The upper spectrum for 
each experiment is the deconvoluted output showing the molecular weight each “envelope” represents.  The 
intensity of each molecular weight provides the total abundance of the “envelope”.   
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APPENDIX A 
TEAR GLUCOSE MEAL STUDIES 
To gauge the blood-tear glucose correlation, meal studies were carried out on non-diabetic and 
diabetic subjects.  The studies consisted of the patient fasting overnight and providing blood and 
tear samples before and after intake of a set amount of sugar drink (Meal).  Samples were taken 
in sets with one set defined as blood, left eye tears, and then right eye tears.  Three sets were 
taken prior to the meal for most of the studies and then about twelve sets after the meal.  Blood 
glucose concentration was determined by either venous blood sampling with use of the glucose 
oxidase method or a pin prick along with the use of a glucose meter.  Tear glucose 
concentrations were obtained by sampling with a one microliter capillary and use of the mass 
spectrometry method described in Chapter 4.  The meal for studies without using the C18 column 
was 1 gram of glucose within the drink per 1 kilogram of the subject’s body weight.  The studies 
with the C18 column had a meal which consisted of an intake of 75 grams of glucose contained in 
the drink, which resembles a glucose tolerance test used to diagnose diabetes.  Meal studies were 
performed on thirteen subjects prior to the use of the C18 column in the glucose method (Figures 
A.1-13) and three studies were performed after the column addition (Figures A.14-16).  The 
figures are arranged to show the deviation from the averaged pre-meal glucose concentrations 
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but also the absolute values.  For each study, the data is separated into the three graphs one each 
for blood glucose concentration, left eye glucose concentration, and right eye glucose 
concentration.  The thirteen studies completed before the final method was established contain an 
average baseline (pre-meal) value of glucose in tears of 150 µM.  It was determined after the 
final method was established that baseline glucose values are on average 28 µM.  The baseline 
values for the experiments prior to the use of the column are more than likely at the limit of 
detection for the method.  All data was used to further the understanding of the tear glucose 
concentrations and helped to provide the conclusions in Chapter 4.  In addition, it can be seen 
that each subject had a different rise and fall of glucose concentration within blood and tears.  
The method was approved by the University of Pittsburgh Institutional Review Board #011108.   
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Figure A.1:  Meal study of subject 1 (non-diabetic) 
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Figure A.2:  Meal study of subject 2 (non-diabetic) 
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Figure A.3:  Meal study of subject 3 (non-diabetic) 
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Figure A.4:  Meal study of subject 4 (non-diabetic) 
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Figure A.5:  Meal study of subject 5 (non-diabetic) 
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Figure A.6:  Meal study of subject 6 (non-diabetic) 
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Figure A.7:  Meal study of subject 7 (non-diabetic) 
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Figure A.8:  Meal study of subject 8 (non-diabetic) 
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Figure A.9:  Meal study of subject 9 (diabetic) 
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Figure A.10:  Meal study of subject 10 (diabetic) 
RIGHT
-1.00
0.00
1.00
2.00
0 50 100 150 200 250
time (min)
%
 C
ha
ng
e 
fr
om
 
Fa
st
in
g
0
81
162
[G
lu
co
se
] (
µM
)M
ea
l
LEFT
-1.00
0.00
1.00
2.00
0 50 100 150 200 250
time (min)
%
 C
ha
ng
e 
fr
om
 
Fa
st
in
g
0
97
194
291
[G
lu
co
se
] (
µM
)M
ea
l
BLOOD
-1.00
0.00
1.00
2.00
0 50 100 150 200 250
time (min)
%
 C
ha
ng
e 
fr
om
 
Fa
st
in
g
0
7981
15962
23943
[G
lu
co
se
] (
µM
)M
ea
l
%
 C
ha
ng
e 
fr
om
 
Fa
st
in
g
[G
lu
co
se
] (
µM
)M
ea
l
%
 C
ha
ng
e 
fr
om
 
Fa
st
in
g
[G
lu
co
se
] (
µM
)M
ea
l
%
 C
ha
ng
e 
fr
om
 
Fa
st
in
g
[G
lu
co
se
] (
µM
)M
ea
l
 
  104
Figure A.11:  Meal study of subject 11 (diabetic) 
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Figure A.12:  Meal study of subject 12 (diabetic) 
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Figure A.13:  Meal study of subject 13 (diabetic) 
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Figure A.14:  Meal study of subject 1 (non-diabetic) with column 
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Figure A.15:  Meal study of subject 10 (diabetic) with column 
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Figure A.16:  Repeat meal study of subject 1 (non-diabetic) with column 
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APPENDIX B 
ANALYSIS OF SILYL CONTAINING REACTION COMPOUNDS 
The ideal method to analyze volatile organic compounds would provide qualitative and 
quantitative analysis of any volatile organic compound and their isomers even in a complex 
mixture.  H3O+ has been used within chemical-reaction mass spectrometry to this end22; 
however, it is susceptible to clustering reactions which complicates analysis.  An alternative 
approach is to use a silyl-transfer reagent.  It has been shown that ionic reaction complexes 
containing a silicon atom have a high exchange of functional groups.23,80-83  The products of the 
chemical reaction between the silyl containing ion and the volatile organic compound could 
provide the differentiation between analytes or tandem mass spectrometry could provide unique 
fragment ions.84  To further this objective, this study explores three silyl transfer reagents. 
 Three silyl containing compounds (hexamethyldisiloxane, tert-butoxy trimethylsilane, 
and 2-trimethylsiloxy-propene) were analyzed with tandem mass spectrometry preceded with 
different ionization techniques.  Hexamethyldisiloxane ((CH3)3SiOSi(CH3)3) was tested due to 
its similarity to water23 and the other two compounds are related to hexamethyldisiloxane.  
Compared to hexamethyldisiloxane, Tert-butoxy trimethylsilane ((CH3)3SiOC(CH3)3) has a 
carbon substituted for a silicone and 2-trimethyldisiloxy-propene ((CH3)3SiOSi(CH3)CH3)  has 
  111
lost CH4.  The three ionization techniques used were electron ionization, atmospheric-pressure 
chemical ionization, and electrospray ionization.  Ions resulting from these techniques were 
subjected to collision-induced-dissociation to determine their structure.  Collision-induced-
dissociation was also performed on the electron ionization ions of hexamethyldisiloxane with 
acetone-d6 and propanal (instead of argon) as the collision gas to determine if isomeric 
determination could be achieved.  
B.1 EXPERIMENTAL 
Hexamethyldisiloxane, 2-trimethylsiloxy-propene, propanal, and acetone-d6 were purchased 
from Sigma-Aldrich (St. Louis, MO).  Tert-butoxy trimethylsilane was purchased from Oakwood 
Products, Inc. (West Columbia, SC).  Argon was purchased from National Valley Gas, Inc. 
(Pittsburgh, PA).  Electron ionization experiments were either performed on the SWISS-484 with 
the ionization source mounted directly on the first quadrupole casing (Figure B.1) or on a triple 
multipole at Extrel CMS (Pittsburgh, PA) with 100 eV set as the ionization energy.  All 
electrospray ionization experiments were performed on the HP LCMS with flow-injection 
analysis.  Injections into the HP LCMS were 1 µL in volume of pure analyte and the flow rate of 
the “mobile phase” was 0.4 mL/min of 50% water and 50% acetonitrile.  The atmospheric-
pressure chemical ionization experiments were performed on the SWISS-484 with a custom built 
source (Figure B.2).  The source is similar to the electrospray source described previously but the 
high-voltage is placed on a corona needle situated in-between the analyte delivery capillary and 
the mass spectrometer capillary inlet.  4.5 kV was placed on the corona needle and a flow rate of 
0.5 µL/min was used through the 25 µm tipped analyte delivery capillary.  All experiments used 
  112
  
Figure B.1:  SWISS-484 with EI source and volatile sample inlet. 
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Figure B.2:  Atmospheric-pressure ionization source for the SWISS-484 
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100% of the compound as the analyte solution.  Tandem mass spectrometry experiments had a 
collision gas pressure about 1 x 10-5 torr.   
B.2 RESULTS AND CONCLUSIONS 
The EI experiments on the three silyl compounds resulted in data similar to research previously 
reported.80,85  With hexamethyldisiloxane as the analyte, m/z values of 147 (loss of a methyl 
group), 131 (loss of a methyl and methane), and 73 (trimethylsilane ion) were observed (Figure 
B.3a).  With tert-butoxy trimethylsilane as the analyte, m/z values of 131 (loss of a methyl 
group), 75 (proposed to be (CH3)3COH2+ due to its isotopic ratio), and 73 (trimethylsilane ion) 
were observed (Figure B.4a).  With 2-trimethylsiloxy-propene as the analyte, observed m/z 
values and the proposed structures for each are m/z 130 [(CH3)3SiOC(CH3)CH2]+, m/z 115 
[(CH3)3SiOCCH2]+, m/z 99 [CH3(CH2)SiOCCH2]+, m/z 85 [CH3SiOCCH2]+, m/z 73 [(CH3)3Si]+, 
and m/z 59 [H(CH3)2Si]+ (Figure B.5a).   
The protonated analyte was observed for both hexamethyldisiloxane (Figure B.3b) and 
tert-butoxy trimethylsilane (Figure B.4b).  In the tert-butoxy trimethylsilane spectrum m/z 91 was 
also observed.  This ion is attributed to fragmentation in the source and proposed due to its 
isotopic ratio to be [(CH3)3SiOH2]+.  In the 2-trimethylsiloxy-propene spectrum only m/z 102 
was observed (Figure B.5b).  Conflicting data was obtained for the structure of this ion.  In the 
fragmentation study on m/z 102 (Figure B.6c) loss of 29 (m/z 73) and 57 (m/z 45) are observed.  
With these observed fragments, [(CH3)3SiOCH]+ is proposed to be m/z 102.  However, the 
isotopes of m/z 102 (i.e., m/z 103 and 104) are not consistent with having silicon in the molecular 
formula.  The other compound’s fragmentation studies proved to be consistent with the 
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protonated analyte (Figure B.6).  The ESI data obtained on the HP LCMS were identical to the 
APCI data obtained on the SWISS-484. 
Fragmentation studies on the EI ions of hexamethyldisiloxane were performed with 
organic carbonyl compounds as the collision gas.  [(CH3)3SiOSi(CH3)2]+, 
[(CH3)2SiOSi(CH3)CH2]+, and [(CH3)3Si]+ were selected in Q1 and allowed to collide with d6-
acetone or propanal in the collision cell.  The main change from the traditional CID spectrum 
with argon as the collision gas is the presence of the adduct of the Q1 selected ion and the 
organic compound.  When [(CH3)3SiOSi(CH3)2]+ is selected, in addition to the adduct the loss of 
a methyl group from the adduct is observed in both carbonyl cases (Figure B.7).  Also a unique 
ion is observed for each carbonyl.  For d6-acetone, the exchange of CD3 groups is apparent at m/z 
137, while for propanal the loss of an ethyl group from the adduct is observed.  When 
[(CH3)2SiOSi(CH3)CH2]+ is selected additional ions are observed but none could be attributed to 
the carbonyls (Figure B.8).  When [(CH3)3Si]+ is selected and d6-acetone is used as the collision 
gas the exchange of the deuterated methyl group is once again observed (Figure B.9).  If 
propanal is used instead the only additional ion is the loss of 14 from the adduct. 
At present the only apparent isomer differentiation is with the use of 
hexamethyldisiloxane, however a more intense signal would be beneficial.  Ideally, 
fragmentation of the adduct ions would provide a more intense signal and possibly better 
compound distinction from all three silyl ions.  To perform this analysis on a triple multipole 
instrument the adduct ions would need to be formed prior to Q1. 
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Figure B.3:  Ionization of hexamethyldisiloxane by (a) EI and (b) APCI 
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Figure B.4:  Ionization of tert-butyoxy trimethylsilane by (a) EI and (b) APCI 
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Figure B.5:  Ionization of 2-trimethylsiloxy-propene by (a) EI and (b) APCI 
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Figure B.6:  CID of (a) protonated hexamethyldisiloxane, (b) protonated tert-butoxytrimethylsilane, and (c) 
m/z 102 from the APCI of 2-trimethylsiloxy-propene. 
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Figure B.7:  CID experiments of [(CH3)3SiOSi(CH3)2]+ with the collision gas being (a) argon, (b) d6-acetone, 
and (c) propanal. 
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Figure B.8:  CID experiments of [(CH3)2SiOSi(CH3)CH2]+ with the collision gas being (a) argon, (b) d6-
acetone, and (c) propanal. 
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Figure B.9:  CID experiments of [(CH3)3Si]+ with the collision gas being (a) argon, (b) d6-acetone, and (c) 
propanal. 
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